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Abstract
Matrix metalloproteinases (MMPs), such as stromelysin, have been linked the degra-
dation of articular cartilage in normal and pathologic tissue. Elevated levels of MMP pro-
duction and mRNA expression have been detected in patients with rheumatoid arthritis,
osteoarthritis and traumatic joint injury as well as in developing tissue and normal growth
plate cartilage. While MMPs have been shown to degrade purified matrix macromolecules
in vitro, their action against the matrix of intact cartilage has not been well established.
The objectives of this thesis were threefold: (1) to characterize the ability of MMPs to
degrade cartilage matrix constituents of intact cartilage; (2) to quantify the effects of this
degradation on the functional biophysical properties of cartilage; and (3) to evaluate the
ability of synthetic and natural MMP inhibitors to modulate these changes in composition
and biophysical properties.
Bovine cartilage explants were treated with recombinant human stromelysin-1 and
changes in biochemical, biomechanical, and physicochemical properties as well as histolog-
ical appearance were assessed. Stromelysin treatment resulted in a time and dose dependent
loss of proteoglycan fragments from the explants, increased degradation and loss of type IX
collagen, and a concomitant swelling of the tissue. Histological examination demonstrated
that proteoglycan loss proceeded inward from the exposed tissue surfaces, with a marked
boundary between degraded and undegraded tissue. Stromelysin treatment resulted in
marked decreases in equilibrium modulus and dynamic stiffness and a substantial increase
in hydraulic permeability after three days in culture. Measurement of dynamic streaming
potential showed that changes due to stromelysin treatment were strongly dependent on
compression frequency, with dramatic decreases seen at high frequency prior to changes in
mechanical properties, and little initial change seen at low frequency.
Cartilage from rabbit stifle joints which were exposed to stromelysin for 1 hour
in vivo showed little difference in proteoglycan content from cartilage from contralateral
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control joints, while synovial fluid proteoglycan content from stromelysin treated joints
was significantly higher than that of controls. Histological examination revealed that loss
of proteoglycan, as indicated by both toluidine blue and FVDIPEN antibody staining, oc-
curred primarily in a narrow region of the tissue near the articular surface. Consequently,
the mechanical properties, such as equilibrium modulus and dynamic stiffness, of carti-
lage samples from treated joints did not differ significantly from those of control joints,
while electromechanical properties, such as streaming potential and electrokinetic coupling
coefficient, of cartilage from treated joints were degraded significantly compared to con-
trols. Systemic administration of a synthetic MMP inhibitor signficantly decreased release
of proteoglycan fragments to synovial fluid, inhibited loss of proteoglycan as indicated
by toluidine blue and FVDIPEN antibody staining, and prevented changes in cartilage
electromechanical properties due to intraarticular injection of stromelysin.
The degradation of cartilage matrix by endogenous MMPs was characterized by
treatment of explants with 4-aminophenylmercuric acetate (APMA) to activate native MMPs
or by treatment with interleukin- 10 (IL- 10) or retinoic acid (RA), which upregulate produc-
tion of MMPs by chondrocytes, and may increase levels of other endogenous proteinases.
Treatment with APMA resulted in significant loss of proteoglycan by 1 day in culture and
in significant swelling response by 3 days in culture. Matrix degradation was manifest in
changes in sample mechanical and electromechanical properties. Both a synthetic MMP
inhibitor and the native MMP inhibitor, TIMP, significantly inhibited proteoglycan loss,
swelling response, and changes in physical properties due to APMA treatment. Treat-
ment with IL-1 /3 and RA induced significant loss of proteoglycan after 4 days in culture.
Treatment with IL-10 resulted in an increased swelling response after 8 days in culture,
while RA treatment did not. Both IL-1/3 and RA treatments resulted in significant changes
in tissue mechanical and electromechanical properties which were partially modulated by
addition of TIMP to the culture media. Use of synthetic inhibitors also partially modulated
proteoglycan loss from IL-10 and RA treated tissue. Analysis of fragments in the culture
media from these samples indicated that cleavage of proteoglycan did not occur at the
VDIPEN-FFGV site associated with MMP activity, but rather at the NITEGE-ARGSVL
site on the aggrecan core protein. This was the only proteinase activity observed against
aggrecan in this system, and it was partially inhibited by the addition of a synthetic MMP
inhibitor to the culture media.
Thesis Supervisor:
Alan J. Grodzinsky, Professor of Electrical, Mechanical, and Bioengineering, MIT
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Chapter I
Introduction
1.1 Articular Cartilage
Articular cartilage is an avascular, aneural, alymphatic, connective tissue which covers
the ends of bones in synovial joints. Its primary functions are to lubricate the surface
of articulating joints and to distribute stresses generated by muscle contraction and body
weight over bone surfaces. Articular cartilage is a porous, highly hydrated material, with
water content of approximately 80% by volume. The solid component of cartilage consists
of cells, called chondrocytes, and an extracellular matrix, with cell concentration being
approximately 100 x 106 cells/ml [117]. The extracellular matrix is composed primarily
of hyaluronic acid, various proteoglycans including aggrecan, decorin, and biglycan, and
collagen types II, IX, and XI. A schematic diagram of cartilage structure is shown in figure
1.1 [57].
The mechanical properties of articular are related to its complex physical structure.
The long, thin, rope like collagen fibrils present in the matrix serve to strengthen the tissue
in tension and shear. The large proteoglycan, aggrecan, associates non-covalently with
hyaluronan to form a network of large aggregates throughout the tissue. Branching off from
the aggrecan core protein are many glycosaminoglycan (GAG) chains which contain sulfate
and carboxylic acid charge moities, which endow the tissue with a significant charge density
of approximately 0.1 to 0.2 moles of charge per liter of fluid [80]. Under physiological
conditions all of these charge groups are effectively ionized. The attraction of positive
counterions from the surrounding fluid to the negative charges fixed on the matrix creates
an electrical double layer at the surface of the GAG chains. When compressive strains
are applied to the tissue, the effective distance between double layers is decreased. As
the double layers overlap, significant electrostatic repulsion develops which is translated
into a marked increase in tissue stiffness [48]. It is estimated that as much as one half of
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Figure 1.1: Schematic illustration of cartilage extracellular matrix
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equilibrium tissue stiffness is attributed to electrostatic repulsion of GAG chains [39].
The fluid phase of the highly hydrated matrix also has a significant impact on the
physical properties of articular cartilage. As the tissue is compressed, fluid leaves the tissue.
The frictional forces which result from fluid movement relative to the solid phase tend to
stiffen the tissue. As loading time is decreased (or loading frequency is increased), the
velocity of the fluid relative to the matrix increases and thus frictional forces increase as
well. This results in a dynamic tissue stiffness that is highly frequency dependent.
Fluid motion and the high charge density immobilized on the matrix combine to
produce a phenomenon known as streaming potential. As previously stated, the charge
groups fixed on the matrix cause a high density of mobile ion space charge to develop in the
fluid surrounding the matrix in order to preserve electroneutrality (Donnan equilibrium).
When strains are applied to the tissue, fluid motion thus separates the mobile fluid phase
cations from the immobilized matrix anions. This charge separation results in the generation
of local electric fields in the tissue. The sum of all the local electric fields across the tissue
due to fluid streaming is called the streaming potential. Fig 1.2 illustrates the generation of
a streaming potential in response to a uniaxially applied displacement [40].
1.2 Cartilage Biochemistry
The chemical constituents of the articular cartilage matrix are of extreme importance when
discussing tissue function. The physical properties of the tissue are strongly dependent
on the structure and organization of the macromolecules in the matrix [51]. These macro-
molecules include proteoglycans, collagens, and other proteins such as link protein, and
hyaluronic acid. These matrix constituents are connected by chemical and mechanical cross
links to form an effectively continuous three-dimensional network throughout the tissue.
In addition, each type of matrix macromolecule has its own distinct chemical nature which
contributes to the bulk properties of the material.
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Figure 1.2: Illustration of streaming potential: mobile counterions present in the fluid phase
are separated from charges bound to matrix when a mechanical stress or displacement is
applied.
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1.2.1 Proteoglycans
As a group, all proteoglycans in articular cartilage have some structural similarities. As the
name implies, proteoglycans (PGs) are macromolecules composed of proteinous regions
and glycosylated regions. Articular cartilage PGs consist of carbohydrate chains which are
covalently bonded to a protein core. The nature of both the core protein and the chains varies
with PG type. For the purposes of this discussion, cartilage PGs are divided into two types:
large aggregating PGs (aggrecan); and small PGs (decorin, biglycan, and fibromodulin).
Aggrecan
The most abundant proteoglycan in articular cartilage by weight is the large aggregating
proteoglycan, or aggrecan. Aggrecan is a macromolecule of considerable size, with total Mr
of one to three million [56]. The core protein Mr is approximately 300,000 and extends to a
length of approximately 300 nm [51]. In addition, there are approximately 100 chondroitin
sulfate chains and 30 keratan sulfate chains bound to the protein core which provide the
balance of molecular mass.
The aggrecan molecule is divided into five structural units, with three globular
domains and two interglobular domains, as is shown in figure 1.3 [52]. The N-terminal
domain on aggrecan, G 1, associates with hyaluronan and link protein to form a link stabilized
(non-covalent) aggregate. G1 is a globular domain with three folds. The N-terminal fold
is an immunoglobulin fold (Ig fold) while the remaining two are a tandem repeat sequence
characterized by a disulfide bond induced double loop [51]. The Mr of the G1 core is
approximately 39 kDa and it is thought to bind a small number of keratan sulfate chains.
Progressing towards the C-terminal end, there is a short extended domain called
the interglobular domain. This domain is approximately 21 nm long as has an Mr of 12
kDa. It is the site of attachment for several keratan sulfate chains and serves to link G1 to
the second globular domain, G2. G2 is similar in structure to G1, although the Ig fold is
omitted, leaving G2 with 2 folds. The G2 Mr is approximately 25 kDa and G2 contains
slightly more keratan sulfate than does G1.
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Figure 1.3: Schematic diagram of aggrecan structure [16].
The largest domain in aggrecan is the chondroitin sulfate bearing domain which
extends from the C-terminal side of G2. The length of this domain is approximately 260
nm with a core protein Mr of 195 kDa. Adjacent to the G2 domain is a small 15 kDa region
in which keratan sulfate chains attach to the core, and this is followed by a long 180 kDa
region where chondroitin sulfate chains are attached. The C-terminal group is the globular
domain G3, which bears little resemblance to G1 or G2. There appears to be only one loop
in G3 which has an Mr of 25 kDa. G3 shows some weak carbohydrate affinity and it is thus
postulated that it may play a role in matrix organization.
Small Proteoglycans
The small proteoglycans of primary interest in articular cartilage are decorin, biglycan, and
fibromodulin. Both decorin and biglycan contain dermatan sulfate GAG chains as well as
the chondroitin sulfate and keratan sulfate chains common to aggrecan. The GAG chain
binding region lies in the N-terminal section of both molecules. Decorin and biglycan have
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similar, but non-identical structures. Both have a core protein Mr of 40 kDa. Decorin, with
a single CS chain has a total Mr of approximately 85 kDa, while biglycan, with a 2 CS
chains has a total Mr of 130 kDa [56,57]. Decorin is known to bind to type IX collagen
fibrils during formation and may inhibit the production of such fibrils. Though structurally
similar, biglycan appears to have no such function. Additionally, it has been observed that
both decorin and biglycan have the ability to immobilize certain growth factors. Thus, it is
possible that these molecules play a key role in regulating matrix growth [57].
1.2.2 Collagens
As may be expected, collagens play a key role in the matrix structure of articular cartilage.
Collagen fibers themselves are very strong in tension and in large part their function is
to resist the osmotic swelling pressure created by the highly charged proteoglycans. This
structure allows the collagen to provide strength when the tissue is exposed to tensile and
shear forces. The collagens most prevalent in articular cartilage are types II, IX, and XI.
Together, these three types make up 99% by weight of all the collagen present in articular
cartilage [33]. Of the three, type II is by far the most common, constituting 90-95% of all
the collagen in the tissue.
Type II Collagen
Type II collagen is found throughout the articular cartilage matrix and it forms the framework
for the entire tissue. The type II network serves to entrap proteoglycans within the tissue
and restrain tissue swelling due to osmotic pressure of the charged proteoglycans. The
type II molecule is composed of three identical a 1(II) chains wound together. The type II
collagen molecule consists of a single continuous triple helical domain, with with unwound
telopeptide regions on both the C- and N-termini. Type II molecules assemble into fibrils
by means of cross-linking hydroxylysyl pyridinoline residues in telopeptide regions. This
structure gives type II collagen a distinctive banded structure which repeats every 67 nm
[33]. The continuous assembly of type II collagen molecules into fibrils results in an
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increase in fibrillar diameter with age, from less than 20 nm in fetal tissue and 50 to 100
nm in adult tissue. The type II fibril orientation varies with location in the tissue. In the
uppermost regions of the tissue, near the articular surface, the fibrils are oriented tangential
to the surface, while deeper in the tissue, the fibrils are essentially oriented randomly.
Type XI Collagen
Type XI collagen constitutes approximately 3% by weight of all the collagen in the articular
cartilage matrix [33]. Biochemical and immunochemical data suggest that the primary
function of type XI collagen is to act as the core for type II fibrils. Unlike type II, type XI
collagen is heterogeneous trimer, composed of three chains al(XI), ca2(XI), and a3(XI).
The a3(XI) chain is indistinguishable from a• (II), which may aid in its function as the core
molecule of type II collagen. The a 1 (XI) and a2(XI) chains are composed of separate and
distinct amino acid sequences [33].
An interesting feature of type XI collagen is that the molecule retains the N-terminal
propeptide during normal function. The propeptide segment is beyond the N-terminal non-
collagenous region and contains a short collagenous segment followed by a globular region.
The function of this region is unclear, but it has the effect of preventing further lateral
expansion of the fibrils. This N-terminal segment is also the region in which interfibril-
lar cross-linking takes place, with the attachment occurring by means of a hydroxylysyl
pyridinoline residue.
Type IX Collagen
Type IX collagen represents 1% of the collagenous protein in mature articular cartilage.
There is evidence that as much as 10% of the collagen in fetal articular cartilage is type
IX [32], implying that it may play an important role in matrix assembly. Type IX collagen
is a heterotrimer of chains al(IX), a2(IX), and a3(IX). The molecule consists of three
collagenous domains, COL1, COL2, and COL3, which are woven in a triple helix, and four
globular domains, NC1, NC2, NC3, and NC4, which are located in between the collagenous
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domains and at the ends of the molecule.
The type IX molecule itself is both collagen and proteoglycan. In the NC3 domain
there is a site of attachment for a chondroitin sulfate chain which has ionizable charge
groups. The N-terminal region of the COL2 domain play an additional role in the function
of type IX collagen. This region appears to contain the sites of attachment which cross link
type IX collagen to type II collagen. All three type IX chains, a l(IX), a2(IX), and a3(IX),
contain the hydroxylysine residues which covalently bind to the a (II) chain on the type II
molecule [31,134]. This method of attachment results in the type II and type IX molecules
being oriented in an antiparallel fashion. Such attachment has been observed by electron
microscopy [124].
1.2.3 Hyaluronic Acid
Hyaluronan is the long chain backbone macromolecule to which aggrecan molecules attach
to form aggregates. Hyaluronate molecules are extremely large with Mr up to 5 to 6 x 106
and a length of up to 10 /m. Typical sizes for hyaluronan are an Mr of 3 to 6 x 105 and a
length of .5 to 1 4/m [52]. As expected, the size of the hyaluronic acid chain determines how
many proteoglycans can bind to the molecule. Since GAG chains typically extend from the
core proteins of proteoglycans, steric hindrance is an important determinant of molecular
packing. It is estimated that these hindrances allow for one aggrecan molecule per 7 kDa
of hyaluronate chain [52]. As such, the largest of the hyaluronate molecules can bind from
400 to 800 aggrecan molecules. The Mr of such aggregates can be as much as 100 x 106
kDa [56].
As previously mentioned, proteoglycans are held in the matrix by means of an
attachment between the GI domain of aggrecan and the hyaluronate backbone. This
attachment is further enhanced by a small polypeptide known as link protein which binds
to both the G1 domain of aggrecan and to hyaluronate. Link protein is similar in size and
composition to the Gl domain of aggrecan. Like the G1 domain, it consists of an Ig fold
and a protein tandem repeat sequence. It is postulated that the primary role of link protein
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may be to increase the stability of aggrecan/hyaluronan complexes in the first stages of
aggregation, when the binding of proteoglycan to hyaluronate may be incomplete.
1.3 Osteoarthritis
Osteoarthritis (OA) is a degenerative joint disorder which affects a significant portion of our
population. In 1980 it was estimated that 61 million Americans had some degree of arthritis
in the hands or knees as detected by x-ray[59]. Approximately one third (23 million) of
such cases are severe enough that they require medical attention or inhibit normal lifestyle.
Among those of age 55 to 64, 63% of all men and 75% of all women have evidence of
OA, and of those over 75 frequency rises to 80% of all men and almost 90% of all women.
From 15% to 30% of all visits to general practitioners may be attributed to loss of mobility
cause by OA. In 1980 the annual cost of treatment for OA was estimated at $8.6 billion. For
most patients, treatment of OA typically involves the use of nonsteroidal antiinflammatory
drugs (NSAIDS) which tend to reduce joint pain and swelling [ 11]. NSAIDS are effective
at treating the symptoms of OA, but do nothing to alter the course of the disease [126]. At
the present time, there is no effective way to stop the process of degeneration of OA.
The biochemical events which contribute to OA are not understood completely.
There are a large number of enzymes, hormones, growth factors, cytokines, and mediators
as well as mechanical factors which govern the synthesis and breakdown of the matrix. In
OA, cartilage matrix composition is altered substantially, weakening the tissue considerably,
to the extent that mechanical wear from joint motion can result in erosion of cartilage down
to the bone surface [14]. In its degenerated state, OA cartilage exhibits dramatically different
biochemical, physicochemical, mechanical, and electromechanical properties from normal
tissue. OA cartilage shows a distinct decrease in proteoglycan content [19,83], marked
collagen network fibrillation [33,44], increases in tissue hydration [3,78], and loss of
compressive stiffness [3,58,102]. The role of enzymatic degradation in OA has been
studied, but is not completely understood. In normally functioning tissue, there is a balance
between levels of endogenous proteinases and inhibitors, while in OA, proteinases are
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in excess compared to levels of inhibitors. It has been suggested [27] that families of
enzymes, including metalloproteinases [20,92,96,100], serine proteases [66], and a novel
"aggrecanase" [110] contribute to cartilage degradation in OA. Given that various enzymes
have specific expression patterns [23,76], and some act as activators of other enzymes
[16,119,120], it seems likely that the enzymatic component of OA involves a "cascade" of
activities which work in tandem to degrade the tissue.
1.4 Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are are a family of at least 12 enzymes which are
divided into three main classes: collagenases, gelatinases, and stromelysins. Gelatinases
are not thought to play a major role in degradation of cartilage matrix, however, interstitial
collagenase (MMP- 1) is known to degrade collagen types II and X [127], while stromelysin-
1 (MMP-3) is known to degrade aggrecan [35], link protein [92], and collagen types II,
IX, X, and XI [134]. Both collagenase and stromelysin are produced by chondrocytes and
synovial fibroblasts [23,76,96]. These MMPs are present in elevated levels in cartilage and
synovial fluid of patients with degenerative OA [74,96,98], as well as in animal models
[20,81,100]. Elevated levels have likewise been detected in cases of knee joint injury [74]
and heat shock [123]. There is also evidence of MMP gene expression in early stages of
soft tissue development [12] as well as immunolocalization of MMPs in cartilage growth
plate [13].
Members of the MMP family are synthesized and secreted in a latent zymogen form
which requires activation by proteolytic cleavage of a peptide sequence at the N-terminus
of the molecule [127]. This activation can take place from cleavage by plasmin, trypsin,
or organo-mercurial compounds such as 4-aminophenylmercuric acetate (APMA). Nagase
et al demonstrated that in the presence of APMA, native prostromelysin or procollagenase
will undergo a conformational change which results in the production of an intermediate
which is then self-catalyzed to produce an active form of the enzyme [89]. Previously,
APMA has been used to activate latent MMPs produced by cartilage after treatment with
Section 1.4
-31-
IL- 1 [100] or in animal models of arthritis [99].
1.4.1 Stromelysin
Stromelysin, also known as matrix metalloproteinase 3 (MMP-3), collagenase activator
protein (CAP), proteoglycanase, and transin, is a neutral metalloprotease produced by
chondrocytes and synovial fibroblasts [24,35,76]. It is produced in a latent proenzyme
form which has a molecular weight of 55 kD and can be activated by plasmin cleavage to
produce 45 kD, 22 kD, and 19 kD active forms. These active forms have been shown to be
effective at cleaving several different matrix components in cartilage, including aggrecan
[23,92,100], link protein [92], and collagen types II, IX, X, and XI [134].
Stromelysin has been shown to be present in degraded tissue and has been implicated
in normal tissue turnover, as well as remodeling and development. It has been found in
elevated levels in cartilage and synovial fluid in patients with arthritis [24,75,82], as well
as in animal models [95,96]. Elevated protein and mRNA expression levels have likewise
been detected in cases of mechanical injury [74,101] and heat shock [123]. There is also
evidence of stromelysin gene expression in early stages of soft tissue development [12] as
well as immunolocalization of stromelysin in cartilage growth plate [13].
The manner in which stromelysin degrades articular cartilage matrix constituents
has been researched extensively. In studies conducted on human articular cartilage, it
has been shown that that stromelysin cleaves the Asn3 41-Phe342 bond in the interglobular
domain and the Asp-Iso bond at several sites in the chondroitin sulfate-bearing region of
aggrecan [35]. This has the effect of liberating the G1 domain from the rest of the aggrecan
molecule. In addition, stromelysin has been shown to cleave the histidine-isoleucine bond
in human link protein 3 (LP3) [92]. The combination of these two cleavages has the effect
of liberating the GAG-bearing domains of aggrecan from the domains of the molecule that
are bound to hyaluronate. This action effectively mobilizes the charge groups which were
previously immobilized by their attachment to the matrix.
In addition to aggrecan and link protein, stromelysin has been shown to be effective
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at degrading the three major types of collagen which are present in articular cartilage
matrix. Experiments conducted on bovine epiphysieal cartilage have shown that stromelysin
removed short telopeptide sequences from the a 1 (II) chain as well as effecting the cross links
between chains of type II collagen molecules [134]. Stromelysin cleaves the Ala-Gln and
Val-Met bonds of the cross-linking hydroxylysine segment, effectively eliminating the link.
Stromelysin has similar action against type XI collagen, where it has been seen to cleave the
a1 (XI) chain in the cross-linking hydroxylysine residue. The effects of stromelysin on type
IX collagen, however, are far more pronounced. Stromelysin separates the COL1 domain
from the COL2 and COL3 domains by means of a cleavage in the NC2 region [134]. This
cleavage takes place on the al(IX), oa2(IX), and a3(IX) chains, completely severing the
COLl domain. In addition, it was seen that stromelysin liberated a large globular segment
from the al (IX) chain of the NC4 domain. The action of stromelysin on the cross-linking
hydroxylysine segments of type II collagen also has the effect of decoupling the type IX
and type II molecules [134].
1.4.2 Collagenase
Interstitial collagenase, often called tissue collagenase or MMP-1, is neutral metallopro-
teinase produced by chondrocytes and synovial fibroblasts [23]. The zymogen form of the
enzyme has an Mr or 52 kD which is reduced to 41 kD upon activation. The activate form
degrades matrix collagen types II and X as well as aggrecan [90]. Collagenase is the only
proteinase known to degrade type II collagen in the triple helical domain, and this cleavage
results in significant unwinding of the remaining collagenous protein [60]. The degradation
of aggrecan by collagenase occurs at the Asn341-Phe342 bond in the interglobular domain of
the core protein. This site is identical to the cleavage site of stromelysin on aggrecan.
Collagenase expression in chondrocytes is elevated in osteoarthritis [23,96]. Like-
wise, increased levels of collagenase protein are found in cartilage [90], synovial fluid
and synovial tissue [127] from patients with rheumatoid arthritis and osteoarthritis. Stim-
ulation of cartilage explants by IL-/10 results in increased production of collagenase by
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chondrocytes [90].
1.4.3 Inhibition of Metalloproteinases
There are several naturally occurring inhibitors of MMP activity, including a2-
macroglobulin (a 2-M), and tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1 and
TIMP-2). & 2-M is an extremely large molecule (,750 kDa) produced by the liver and
found in synovial fluid. It inhibits MMPs by presenting a peptide sequence which is
cleaved by the enzyme, then engulfing the enzyme and restricting its access to other sub-
strates. Both TIMPs are also large (-,28 and 22 kDa, respectively) and are produced by
chondrocytes and synovial fibroblasts. The TIMPs inhibit MMPs by binding tightly to the
MMP active site. In healthy joints, there is as much as a two-fold molar excess of TIMP
compared to stromelysin and collagenase [74], while in cases of OA enzyme concentrations
have been seen to exceed levels of native TIMPs ([74,81]. Efforts to use TIMP to inhibit
degradation proteoglycan induced by IL- la in cartilage explants have not been successful,
presumably due to the inability such a large protein to penetrate the dense cartilage matrix.
Although a 2-M and TIMP effectively inhibit metalloproteinases, their size brings
into question their suitability as therapeutic agents. In a tissue explant environment, based
on the partitioning of similarly sized proteins into cartilage [79], the amount of TIMP
or a 2-M which penetrates into the tissue may be as little as 1% or 0.01%, respectively,
of that which is added to the culture media. Consequently, there has been a significant
effort to develop low molecular weight synthetic MMP inhibitors which should penetrate
the cartilage matrix more easily. Several types of synthetic MMP inhibitors have been
developed, including those based hydroxamate compounds [1,113] and others based on
peptide sequences [22,38].
1.5 Models of Cartilage Degradation
Interleukin-1 (IL-1) is an 18 kD cytokine produced by several cell types including en-
dothelial cell, synoviocytes and chondrocytes [114]. Although typically associated with
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inflammatory diseases such as rheumatoid arthritis [24,82], both the a and # forms of IL-1
have been shown to be relevant to degradation in osteoarthritis as well [94,101]. IL-1
interacts with chondrocytes by means of a receptor on the cell surface [21]. Stimulation
of cartilage explants with IL-1 has been shown to result in widespread matrix degradation,
including loss of tissue PGs [4,16,61] and collagens [16]. IL-i treatment directly influ-
ences cell metabolism, decreasing synthesis of PGs [4,16,85,121] and collagens [46,47,122]
while decreasing chondrocyte proliferation [43]. Additionally, IL-1 induces production and
mRNA expression of MMPs in chondrocytes [64], while modulating production of TIMP
[114]. Although tissue treated with IL-1 contains an excess of MMPs, the PG degradation
products which result are not those typically associated with MMP cleavage [108]. These
fragments, however, are similar to those found in human OA patients [1111]. Despite this ap-
parent discrepancy, MMP inhibitors have been shown to be effective at inhibiting cartilage
matrix degradation induced by IL-1 [16,87,113].
The vitamin A derivative all-trans retinoic acid (RA) has also been shown to induce
widespread matrix degradation in cartilage explants. [16,86]. RA stimulation involves
interaction with a nuclear receptor, directly altering DNA transcription [93]. On the tissue
levels, RA treatment results in loss of tissue PGs and collagens [16,17,86] decreased
synthesis of PG [86] and collagens [26,136] by chondrocytes. RA has also been shown
to induce expression and production of MMPs [16], although degradation products from
such systems are not those typically associated with MMP activity (JD Sandy, unpublished
results). This matrix degradation inhibited in the presence of MMP inhibitors, but not in
the presence of inhibitors of cathepsin B [16].
1.6 Overview and Objectives
Many studies have investigated the action of MMPs at either the organ or molecular level.
By comparison, there has been less effort to understand these phenomena on a tissue
level. While is it clear that MMPs are present in cartilage under both normal [12,13] and
pathological [74,96,98] conditions and are quite capable of degrading matrix components
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in solution [35,90,92,134], their action against intact tissue is unknown. Factors such as
transport through the cartilage matrix and effects of intratissue chemical environment are
capable of affecting the way in which these enzymes act on their appropriate substrates. In
addition, the effects of this degradation on the functional physical properties of the tissue
are unknown.
In Chapter II, the effects of degradation by one particular enzyme, stromelsyin,
were characterized. Alterations in tissue composition as assessed by biochemical assays
and histology were correlated with changes in physicochemical, mechanical, and electro-
mechanical behavior. Effects on tissue proteoglycans were assessed by measurements of
tissue GAG content and characterization of the size and nature of the degradation fragments
in culture media. Spatial distribution of proteoglycan loss was determined by histology.
Damage to matrix collagens was assessed by the use of antibodies to collagen types II and
IX to characterize the size and amount of degradation products. Swelling studies were
performed to assess the ability of the damaged collagen network to resist osmotic pressure.
Uniaxial confined compression studies were used to characterize changes in mechanical
and electromechanical behavior due to stromelysin treatment. Therefore, the objectives of
this thesis are to characterize the effects of MMP activity on cartilage at the tissue level and
to quantify the effects of this degradation on the physical properties of cartilage.
Chapter III investigated the effects of stromelysin treatment on intact joint cartilage
in vivo and the modulation of these effects by the systemic administration of an MMP
inhibitor. Rabbit joints were exposed to stromelysin, while changes in cartilage and syn-
ovial fluid proteoglycan content were observed. Cartilage samples removed from these
joints were tested in uniaxial confined compression characterize changes in mechanical and
electromechanical behavior due to stromelysin treatment. In addition, groups of animals
which received this treatment also received intravenous injection of a synthetic MMP in-
hibitor developed at Merck Research Laboratories, in an attempt in evaluate its ability to
inhibit stromelysin in an in vivo environment.
While the work of Chapters II and III detailed the effects of addition of exogenous
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stromelysin on cartilage, Chapter IV focused on the degradative capacity of MMPs native
to the tissue, using APMA to activate endogenous enzymes. The resulting degradation was
characterized by assessing tissue proteoglycan content, and correlating biochemical changes
with alterations in tissue swelling properties as well as mechanical and electromechanical
behavior. In addition, both TIMP, an MMP inhibitor native to cartilage, and MC 1, a synthetic
N-carboxyalkyl peptide inhibitor, were assessed for their ability to inhibit biochemical and
physicochemical changes induced by APMA treatment. The disparity in size between
TIMP (25 kDa) and MC1 (500 Da) allowed for assessment of the importance of transport
through the cartilage matrix to overall inhibitor efficacy in intact tissue.
Many investigators have characterized the the cell-mediated degradation induced
by treatment with IL-10 or RA. Given that both are known to upregulate production of
MMPs, attempts have been made to inhibit degradation in these systems using synthetic
metalloproteinase inhibitors. Chapter V details attempts to compare effects of IL-10
and RA treatment to effects of APMA treatment on cartilage proteoglycan content as
well as changes in swelling properties, mechanical and electromechanical behavior. This
framework allowed for the evaluation of effects of transport on matrix degradation, given
that IL- 10 is a lerge protein (18 kDa) while RA is much smaller (400 Da). In addition, the
ability of TIMP to inhibit biochemical and physical property changes which resulted from
1L-1,3 and RA treatment was assessed.
The subsequent data and analyses in the appendices describe additional work and
methods used to characterize MMP-related cartilage degradation. Appendix A describes the
optimization of tissue treatment and culture parameters for degradation studies. Appendix
B is a survey of physicochemical measurements recorded in an attempt to determine which
were most reflective of changes in swelling behavior. Appendix C describes stromelysin
degradation of cartilage in light of Michaelis-Menten enzyme reaction kinetics. Appendix
D contains an evaluation of several MMP inhibitors in terms of their ability to prevent
degradation induced by stromelysin, APMA, IL- 10, and RA. Both broad spectrum inhibitors
and those with specific target enzymes were used in an attempt to characterize the roles of
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the given enzymes in the observed degradation. Appendix E describes fabrication and use
of a plane-ended indenter for the evaluation of electromechanical properties of cartilage on
intact guineau pig joints. Appendix F is a summary of work characterizing the effects of in
vivo IL-1 fl treatment on the physical properties of rabbit cartilage.
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Chapter II
Changes in Cartilage Composition and Physical Properties
Due to Stromelysin Degradation
2.1 Abstract
Bovine cartilage explants were treated with recombinant human stromelysin-1 (SLN) in
concentrations ranging from 1-500j g/ml (20nM-10/ M) and changes in biochemical,
biomechanical, and physicochemical properties as well as histological appearance were
assessed. SLN treatment resulted in a dose-dependent loss of aggrecan fragments from
the explants, with r40% loss of glycosaminoglycan (GAG) content after 72 hours at a
concentration of 200 nM. N-terminal sequencing of degradation products confirmed that
SLN was responsible for proteoglycan cleavage. Further analysis showed the presence of
elevated levels of type IX collagen fragments within treated explants and in the incubation
media. Histological examination demonstrated that proteoglycan loss proceeded inward
from the exposed tissue surfaces, with a marked boundary between degraded and undegraded
tissue. Physicochemical studies revealed that SLN treatment resulted in tissue swelling,
while treatment with chondroitinase ABC or trypsin did not. SLN treated tissue exhibited
marked decreases in equilibrium modulus and dynamic stiffness and a substantial increase in
hydraulic permeability by 72 hours, with similar kinetics to the loss of GAG. The significant
decreases in equilibrium modulus and dynamic stiffness, together with swelling and the loss
of type IX collagen fragments suggest that the structural integrity of the collagen network
had been compromised. Measurement of dynamic streaming potential showed that changes
due to SLN treatment were strongly dependent in compression frequency, with dramatic
changes seen at high frequency prior to changes in mechanical properties, and little initial
change seen at low frequency. Streaming potential, an electrokinetic phenomenon, was
therefore a more sensitive indicator of initial, focal loss of GAG from the tissue due to SLN
treatment than purely mechanical measurements such as dynamic stiffness.
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2.2 Introduction
Articular cartilage is an avascular, aneural, alymphatic, connective tissue which covers the
ends of bones in synovial joints. Its primary functions are to distribute loads over bone
surfaces and provide a low friction surface over which bones can move. Articular cartilage
is a porous, highly hydrated material, with water content of 70-80% by volume [88]. The
solid component of cartilage consists of an extracellular matrix and a sparse population of
chondrocytes, present in a concentration of approximately 10-100 x 106 cells/ml [117].
The cartilage matrix is composed primarily of hydrated collagen fibrils, highly charged
proteoglycan molecules and other glycoproteins [73,130]. The osmotically swollen matrix
and the high water content are mainly responsible for the complex mechanical behavior
that characterizes the response of the tissue to physiologic loads [65].
In osteoarthritis (OA), the combination of altered cartilage matrix composition and
mechanical wear from joint motion can result in erosion of cartilage down to the bone sur-
face [14]. In its degenerated state, OA cartilage exhibits dramatically different biochemical,
physicochemical, mechanical, and electromechanical properties from normal tissue. OA
cartilage shows a distinct loss of proteoglycan [19,83], marked collagen network fibrilla-
tion [44,102], increases in tissue hydration [3,78], and loss of compressive stiffness [3,58].
The role of enzymatic degradation in OA has been studied, but is not completely under-
stood. It has been suggested [27] that families of enzymes, including metalloproteinases
[20,92,96,100], serine proteases [66], and a novel "aggrecanase" [110] contribute to car-
tilage degradation in OA. Given that various enzymes have specific expression patterns
[23,76], and some act as activators of other enzymes [16,119,120], it seems likely that OA
involves a "cascade" of enzymatic activities which work in tandem to degrade the tissue.
Alterations of biochemical composition and matrix structure which result from en-
zyme activity are manifest in changes in cartilage material properties and physical behavior.
Enzymatic degradation has been shown to result in decreased compressive stiffness [53],
changes in tensile stiffness, strength, and fracture strain [66,112], decreased shear modulus
[55], changes in creep behavior [66,112], and increased indentation displacement [53]. In
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addition, marked decreases in compression-induced streaming potential have been shown
to be particularly sensitive indicators of alterations in matrix proteoglycan composition
associated with enzymatic degradation [41].
Stromelysin-1, also known as matrix metalloproteinase 3 (MMP-3), is a neu-
tral metalloproteinase produced by chondrocytes and synovial fibroblasts [23,76,96].
Prostromelysin has a molecular weight of 55 kD, which can be cleaved by plasmin, trypsin,
or organomercurials to produce 45, 22, and 19 kD active forms which cleave several differ-
ent cartilage matrix components, including aggrecan [35,92], link protein [92], and collagen
types II, IX, X, and XI [134].
Stromelysin has been shown to be present in arthritic tissue and has been implicated
in normal matrix turnover, as well as remodeling and development. It has been found in
elevated levels in cartilage and synovial fluid in patients with degenerative OA [74,96], as
well as in animal models of OA [20,100]. Elevated levels have likewise been detected in
cases of knee joint injury [74] and heat shock [123]. There is also evidence of stromelysin
gene expression in early stages of soft tissue development [12] as well as immunolocalization
of stromelysin in cartilage growth plate [13].
The manner in which stromelysin degrades articular cartilage ECM constituents
has been studied extensively using solutions of isolated matrix molecules in vitro. It has
been shown that stromelysin cleaves the Asn341-Phe342 bond in the interglobular domain of
purified human aggrecan, generating a large chondroitin sulfate-bearing product with the N-
terminal sequence 342 Phe-Phe-Gly-Val, and liberating the GI domain, with the C-terminal
sequence Ileu-Pro-Glu-Asn 341 , from the remainder of the molecule [35,37]. Significantly,
this form of the G1 domain is also present in human articular cartilage, providing evidence
for stromelysin activity in situ [35]. Likewise, stromelysin cleaves the His 16-leu 17 bond of
link protein, and this product has also been detected in human cartilage [91].
In addition to aggrecan and link protein, stromelysin has been shown to be effective
at degrading the three major types of collagen (II, IX, and XI) present in articular cartilage.
Stromelysin removes short telopeptide sequences from the al 1(II) chain, and also cleaves
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the cross-linking hydroxylysine segments, effectively eliminating this link between a 1(II)
chains [134]. Stromelysin separates the COL1 domain from the COL2 and COL3 domains
of type IX collagen by means of a cleavage of the a l(IX), a2(IX), and a3(IX) chains in the
NC2 region [134]. In addition, it was seen that stromelysin could liberate a large globular
segment from the a 1 (IX) chain of the NC4 domain. These combined actions have the effect
of decoupling the type IX-type II collagen complex [134].
Studies on the effects of stromelysin on cartilage matrix constituents have thus far
focused on degradation of isolated matrix constituents in solution. However, the effects
of stromelysin on the composition and physical properties of intact cartilage have received
less attention. The primary objectives of this work were to (1) determine the effects of
stromelysin treatment on the biomechanical and electromechanical properties of cartilage
explants and (2) to correlate the extent and kinetics of changes in these material properties
to changes in certain biochemical, histological and physicochemical characteristics of the
tissue.
2.3 Materials and Methods
2.3.1 Cartilage Explant and Culture
Saddle sections of 1-2 week old calves were obtained from a local abbatoir (A. Arena,
Hopkington, MA) within four hours of slaughter. The femoropatellar groove was isolated
and 3 mm diameter x 1 mm thick cartilage disks were harvested using a dermal punch
(Miltex Instruments, Lake Success, NY) and a sledge microtome (Model 860, American
Optical, Buffalo, NY) as described previously [105]. Recombinant human prostromelysin
(200/Lg/ml) in 25mM Tris HCl, 10mM CaC12, 0.05% Brij 35 and 0.01% NaN3 [129]
was activated with trypsin as described previously [71]. The enzyme had specific activity
as native human gingival fibroblast stromelysin using 3H-transferrin as a substrate [71].
The enzyme was concentrated to ,2 mg/ml using a Centricon 10 ultrafilatration membrane
(Amicon, Inc., Beverly, MA) and diluted into media for tissue culture experiments. Cartilage
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disks were incubated in groups of 4 in 24-well culture dishes (Costar, Cambridge, MA) in
1 ml DMEM (Gibco, Grand Island, NY) containing 100 U/ml penicillin G and 100 /g/ml
streptomycin (Gibco) for approximately 16 hours at 37 oC in a 5% CO 2 atmosphere. Groups
of 4 disks were then placed in 1 ml DMEM containing graded levels of enzymes, including
recombinant human stromelysin-1 (SLN), trypsin (Type III from bovine pancreas, Sigma,
St. Louis, MO), or chondroitinase ABC (protease free, Seikagaku America, Rockville,
MD), and incubated for times up to 72 hours. Upon removal from culture groups of plugs
were allocated for biochemical, histological, physicochemical and biomechanical analyses.
2.3.2 Biochemical Analysis
Disks allocated for biochemical analysis were frozen at -20 C, lyophilized, and digested
with 1 ml of 125 pg/ml papain digestion solution (Sigma) as described previously [105].
20 pl portions of digests and culture media were assayed for sulfated GAG by reaction with
2 ml of dimethylmethylene blue dye solution in polystyrene cuvets (VWR, Boston, MA)
and spectrophotometry (Model A3B, Perkin Elmer, Norwalk, CT) [34] using whale/shark
chondroitin sulfate (Sigma) as the standard.
Aggrecan fragments released into medium during stromelysin digestion were pu-
rified into the D1 fraction of a CsC1 gradient. Core proteins were prepared by enzymic
deglycosylation, Superose 12 chromatography and desalting, and the amino-termini were
determined as previously described [110]. In addition, portions of medium containing
100 /tg GAG were analyzed by chromatography on Sepharose CL-2B in the presence of
4% (w/w) link protein and 4% (w/w) hyaluronan, and fractions were assayed for sulfated
GAG.
Degradation products of type IX collagen were detected in the stromelysin-treated
disks and culture media by western blot analysis. Rabbit antiserum against purified bovine
type IX collagen containing structurally intact COLl, COL2, COL3, NC2, and NC3 do-
mains was produced as described previously [25]. The antiserum reacted specifically with
type IX collagen and did not cross-react with any of the noncollagenous matrix proteins of
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cartilage or with collagen types I, II, III, V, VI, or XI. Tissue slices (14 mg) from stromelysin
treated bovine plugs were extracted with 200 pl1 of a 1% (w/v) sodium dodecyl sulfate (SDS)
solution containing 0.05 M dithiothreitol (DTT) to cleave disulfide bonds. Extracts were
fractionated on SDS-PAGE and electroblotted onto a PVDF membrane for western blot
detection of collagen IX degradation products. The concentration of type IX collagen frag-
ments in culture medium was also quantified by competitive enzyme linked immunosorbent
assay (ELISA) on a microtiter plate using this antiserum.
2.3.3 Histology
Cartilage disks were fixed with ruthenium hexxaammine trichloride (RHT) and stained
with Toluidine Blue 0 as described by Hunziker et al [62]. Each disk was fixed in a 2%
(v/v) glutaraldehyde (Polysciences, Warrington, PA) solution buffered with 0.05 M sodium
cacodylate (Bio-Rad, Richmond, CA) and containing 0.15 M NaCl (pH adjusted to 7.4),
with 0.7% (w/v) RHT powder (Polysciences) added 10 minutes prior to fixation. Samples
were fixed at room temperature for 4 hours and an additional 16 hours at 40 C. Samples were
then washed three times for ten minutes in a solution containing 0.075 M NaCl and 0.1 M
sodium cacodylate (pH 7.4) at room temperature and stored in 1 ml 70% ethanol solution
at 4°C. Tissue was embedded in paraffin and thick (5 + 1 pm) sections were stained with
Toluidine Blue 0 for analysis in the light microscope.
2.3.4 Swelling Studies
The protocol for swelling studies was motivated by the technique used by Maroudas [78]
to compare the swelling of normal and osteoarthritic cartilage. Disks removed from culture
medium were padded briefly with a paper towel to remove surface water, and wet weights
were measured (AE 163 Balance, Mettler Instrument Corp, Hightstown, NJ). Disks were
then twice reequilibrated in a hypotonic saline solution (0.01 M NaCl at pH 7.0) for 1
hour at room temperature. Surface water was again removed and wet weights were mea-
sured. Following wet weight measurements, disks were lyophilized, and dry weights were
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recorded.
2.3.5 Biomechanical and Electromechanical Evaluation
Cartilage disks were placed in an electrically insulating poly(methylmethacrylate) cylindri-
cal confining chamber, similar to that used by Frank et al [41]. The chamber was mounted in
a servo-controlled Dynastat mechanical spectrometer (IMASS, Hingham, MA) which was
interfaced to a computer and frequency generator (Model 5100, Rockland Systems, West
Nyack, NY). Samples were equilibrated in 0.15 M phosphate buffered saline (PBS)(Gibco)
at pH 7.4 containing 100 U/ml penicillin G and 100 pjg/ml streptomycin at room tempera-
ture. Disks were subjected to confined compression between a porous polyethylene platen
and a 6.35 mm Ag/AgCl pellet electrode (Annex Research, Costa Mesa, CA) mounted at
the base of the chamber. An identical electrode was mounted in the surrounding PBS bath.
Disks were first compressed by sequential increments of 0.5-1.5% strain, up to a
maximum of 20% total strain. After stress relaxation, the equilibrium stress correspond-
ing to each increment of static strain was detected with the load cell of the Dynastat and
recorded on the computer. The resultant equilibrium stress was plotted against applied
strain and the slope of the best fit linear regression curve gave the equilibrium confined
compression modulus. At a given static offset strain, sinusoidal strains of <1% amplitude
were superimposed on the static strain at frequencies ranging from 0.01 Hz to 1 Hz. The
resultant oscillatory load was detected by the load cell and the oscillatory streaming po-
tential was detected by the chamber electrodes which were connected to a high-impedance
Universal Amplifier, Model 11-4113-02 (Gould, Inc., Cleveland, OH). Load and streaming
potential were simultaneously recorded by the computer. The amplitude of the dynamic
load was normalized to disk area and to the amplitude of the applied strain to give dynamic
stiffness, while the amplitude of the streaming potential was normalized to the amplitude
of the applied strain [39,40]. Equilibrium modulus and dynamic stiffness data were used
in combination with the method of Frank and Grodzinsky [40] to calculate the effective
hydraulic permeability of the tissue specimen. In all tests the amplitude of the applied
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strain was chosen to be small enough to elicit a linear mechanical response from the sample
[39,40] (i. e. the total harmonic distortion in the measured load was <10%). The porous
platen remained in contact with the sample at all times during the testing cycle.
2.4 Results
2.4.1 Biochemical Analysis
Treatment with SLN induced both a time and dose dependent loss of proteoglycan con-
stituents from bovine cartilage explants (Fig 2.1). The data are reported as GAG remaining
in the tissue normalized to the total GAG (tissue + media GAG) at that time point, versus
time in culture for disks incubated in media containing SLN concentrations ranging from 1
to 500 /g/ml (20 nM to 10MM). Control tissue at t= 0 contained 270 +31 /g GAG/mg dry
weight. For comparison between SLN concentrations, the time course of GAG loss was
fit to an exponential of the form e- t/', giving decay times ranging from 344 hr at 1 /tg/ml
to 6.6 hr at 500pg/ml SLN. GAG loss clearly increased with SLN dose, with maximal loss
achieved in 72 hours for concentrations exceeding 100 /g/ml. Control disks incubated in
DMEM alone showed little GAG loss. By comparison, disks incubated in media contain-
ing 100 pg/ml trypsin demonstrated maximal GAG loss in approximately 3 hours, while
disks incubated with 100 tg/ml SLN and a two-fold molar excess of tissue inhibitor of
metalloproteinases (TIMP) showed GAG loss that was indistinguishable from controls.
To examine the effect of SLN treatment on the structure of the released aggrecan,
media from the disks exposed to 100 /g/ml SLN for 72 hours was first evaluated for
aggregability with hyaluronan on associative Sepharose CL-2B. The profile (Fig 2.2A)
showed that the fragments eluted as a broad peak over the Kay range from 0.3 to 0.7 and
greater than 95% were non-aggregating. This indicated that stromelysin had cleaved the
aggrecan to separate the chondroitin sulfate-rich region from the hyaluronan binding region,
and additionally had cleaved the chondroitin sulfate-rich region in several places. This
interpretation was supported by N-terminal sequence analysis of the aggrecan fragments
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which gave evidence for at least two cleavage products (Fig 2.2B). One sequence, detected
at 5 pmol was FFGVXGXE and this is consistent with the known interglobular cleavage
of the Asn341-Phe3 42 bond in human aggrecan [35,37]. Another sequence, detected at
about 10pmol, was IXGLP, and this is consistent with cleavage between aspartic acid
and isoleucine residues in the sequence GVEDISGLP, which is present in the chondroitin
sulfate-rich region of the bovine aggrecan core protein [2]. N-terminal sequencing showed
no evidence of cleavage products which could not be attributed to SLN.
In addition to aggrecan degradation, SLN treatment resulted in degradation of type
IX collagen, as evidenced by the presence of type IX collagen fragments in the culture media
of disks treated with 100 pg/ml SLN for 72 hours (Fig 2.3A). The ELISA showed that the
level of immunoreactive type IX collagen fragments in the culture media of treated tissue
was three times higher than that of controls. Western blot analysis (Fig 2.3B) indicated that
more of the immunoreactive type IX collagen fragments were extracted from SLN-treated
cartilage disks as compared to that of non-treated controls. The identity of each type IX
fragment and the sites of SLN cleavage remain to be determined. However, the fragments
are large and do not appear to be equivalent to those produced in vitro from monomeric
type IX collagen molecules by SLN [134]. Similar analyses using anti-type II collagen
antibodies also revealed the presences of elevated levels of type II collagen fragments in
extracts of treated explants and in the incubation media (data not shown).
2.4.2 Histology
The loss of proteoglycan constituents from SLN treated disks as determined by biochemical
analysis was reflected in the absence of toluidine blue staining of SLN-treated disks (Fig
2.4B) compared to that of untreated disks (Fig 2.4A). While control disks showed toluidine
blue throughout the tissue, those treated with SLN showed an absence of stain most pro-
nounced in the surface region at early times in culture, consistent with a substantial loss
of GAG. Thus by 24 hours of treatment with 100 pg/ml SLN, the loss of toluidine blue
stained GAG had progressed into the upper - 100 pm of the tissue, with a marked boundary
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Figure 2.1: Normalized GAG loss from cartilage disks incubated in DMEM with graded
levels of recombinant human stromelysin-1 (SLN), 100 /g/ml SLN + 100 jg/ml TIMP, or
100 Ig/ml trypsin. Data are mean ± SD (n=4), reported as GAG remaining in the tissue
normalized to total GAG (tissue + media GAG) at each time point. Solid lines are best fit
singles exponential decay curves of the form le- t/'. The best fit decay times are 7 = 344,
130, 52, 26, and 6.6 hr for respective SLN concentrations of 1, 10, 50, 100, and 500 ,/g/ml;
T = 2.8 hr for 100 jg/ml trypsin, -= 624 hr for 100 tig/ml SLN + 100 jg/ml TIMP and
7 = 1019 hr for DMEM alone.
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between degraded and undegraded regions. The section shown in Fig 2.4 is a magnified
view which shows only a portion of the disk; full cross-section views at 24, 48, and 72
hours [97] indicate that GAG loss had started at the periphery and progressed into the plug
from all surfaces exposed to SLN.
2.4.3 Swelling Studies
Swelling of tissue incubated in the presence of 100/ g/ml SLN, 50 pg/ml trypsin, or
0.1 Units/ml chondroitinase ABC was quantified as the ratio of plug wet weight in 0.01 M
NaCl to wet weight in DMEM (Fig 2.5). Untreated plugs swelled by 6-7% in hypotonic
saline at all time points, while those treated with 100 p/g/ml SLN showed increased swelling
with time up to a maximum of 25% after 72 hours in culture. Plugs treated with 50 pIg/ml
trypsin or 0.1 Units/ml chondroitinase ABC showed swelling that was indistinguishable
from controls. Trypsin treatment resulted in nearly complete GAG loss by 4 hours, while
Chondroitinase ABC treatment resulted in 50% GAG loss by 72 hours (data not shown),
with GAG loss proceeding from the surfaces into the tissue in a front like manner (similar
to that in Fig 2.4), as described previously [41]. Given that both trypsin and chondroitinase
ABC treatment induced significant GAG loss, it seems likely that the increased swelling of
SLN-treated disks is not related to loss of proteoglycan constituents.
2.4.4 Biomechanical and Electromechanical Properties
Treatment with 100 pg/ml SLN resulted in a dramatic decrease in the equilibrium confined
compression modulus, HA (Fig 2.6A). The modulus of control disks was 0.89 + 0.25 MPa
at time t = 0 and remained essentially constant over 72 hours in culture. In contrast the
modulus of disks incubated in the presence on 100 pig/ml SLN decreased to 10% of the
initial value by 72 hours (Fig 2.6A), with kinetics similar to those of GAG loss for a
100 pg/ml SLN dose (see Fig 2.1). The hydraulic permeability, k, of these same disks (Fig
2.6B) was calculated from the measured equilibrium modulus (Fig 2.6A) and the measured
dynamic stiffness (Fig 2.7A), as previously described [40]. The hydraulic permeability
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Figure 2.2: A: Sepharose CL-2B fractionation of culture media. A portion of medium
from disks treated with 100 pg/ml SLN for 72 hours containing 100 pg GAG was mixed
with 4% (w/w) hyaluronan and 4% (w/w) link protein and fractionated under associative
conditions. Also shown is the elution profile of calf aggrecan (AID 1) fractionated under the
same conditions. B: Schematic diagram showing suggested sites of stromelysin cleavage
of bovine aggrecan. The sequences and residue numbers shown are based on bovine data
obtained in the present work and the original human cDNA sequence.
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Figure 2.3: A: ELISA of immunoreactive type IX collagen fragments in the culture media
from disks treated with 100 pg/ml SLN for 72 hours, using anti-bovine type IX collagen
antibodies. B: Western blot analysis of immunoreactive type IX collagen fragments from
the extracts of tissue slices (1% SDS, 0.05 M dithithreitol) taken from disks treated with
100 ipg/ml SLN for 72 hours.
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of control disks was 1.08 ± 0.19 x 10-15 m2(Pa.s)- 1 at time t = 0 and remained constant
over three days in culture. However, the permeability of disks incubated in the presence of
100 p/g/ml SLN markedly increased with time to 15 times that of control disks at 72 hours.
Similar to equilibrium modulus, magnitude of dynamic stiffness decreased dra-
matically after treatment with 100 pg/ml SLN (Fig 2.7A). Applying constant amplitude
sinusoidal strains in displacement control, the measured dynamic stiffness and stream-
ing potential (Fig 2.7B) increased monotonically with frequency, as described previously
[39,40]. In the present experiments, the dynamic stiffness of control disks at t= 0 was
4.40 ± 0.84 MPa at 0.01 Hz and 11.56 ± 1.67 MPa at 1 Hz, and did not change significantly
over 72 hours. In contrast, the dynamic stiffness of disks incubated in 100 Jtg/ml SLN de-
creased to -, 10% of initial values after 3 days in culture. As with equilibrium modulus, the
kinetics of changes in dynamic stiffness were similar to those of GAG loss for a 100 ig/ml
SLN dose (see Fig 2.1). The relative decrease in dynamic stiffness with time in culture was
independent of frequency in the 0.01 to 1 Hz range.
Electromechanical measurements revealed that streaming potential magnitude also
decreased dramatically for disks treated with 100 Ig/ml SLN (Fig 2.7B). Initial values
of streaming potential ranged from 0.10 ± 0.02 mV/% at 0.01 Hz to 0.33 ± 0.05 mV/% at
1 Hz. The streaming potential of control disks did not vary significantly during time in
culture at any frequency, while that of treated plugs decreased to 30% and 10% of initial
values at 0.01 Hz and 1 Hz respectively after 3 days. In marked contrast to dynamic
stiffness, the amount by which the streaming potential of disks treated with 100 jag/ml SLN
decreased with time showed a marked frequency dependence. At high frequency (1 Hz), the
streaming potential decreased quickly with time in culture while at low frequency (0.01 Hz)
the decrease in streaming potential was less rapid.
2.5 Discussion
The combined results of Figs 1 and 2 strongly suggest that SLN is responsible for the
proteoglycan loss seen in our studies. The dose dependence of GAG loss and the absence
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Figure 2.4: Light micrographs of cartilage disks incubated in DMEM alone for 72 hours (A)
and DMEM with 100 tg/ml SLN for 24 hours (B), represented at 100 x. SLN treatment
resulted in an apparent front of enzymatic digestion moving inward from all exposed
specimen surfaces, shown by the absence of toluidine blue stain for GAG. (5 pm section;
bar= 100 pm; V: tissue surface.)
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Figure 2.5: Ratio of wet weight in 0.01 M NaC1 to wet weight in DMEM for samples
incubated in DMEM alone, DMEM with 100 jig/ml SLN, DMEM with 50 jig/ml trypsin or
DMEM with 0.1 Units/ml chondroitinase ABC. Data are mean ± SD.
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Figure 2.6: Equilibrium modulus (A) and hydraulic permeability (B) of cartilage disks as
a function of time in culture. Disks were incubated in DMEM alone (dotted line) or in
DMEM with 100 p/g/ml SLN (solid line). Data are mean + SD (n= 4); mean values are
normalized to the value at t = 0.
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Figure 2.7: Dynamic stiffness (A) and streaming potential (B) of cartilage disks as a
function of time in culture. Data are mean + SD (n = 4); mean values are normalized at
each frequency to the value at t = 0.
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of loss seen when TIMP was added simultaneously with SLN demonstrate that the GAG
loss was induced by the addition of SLN. Moreover, the presence of specific SLN-generated
aggrecan cleavage products in culture media and the lack of detectable cleavage products
generated by other proteinases further suggests that direct SLN cleavage of aggrecan oc-
curred within the tissue during culture. This is of special interest, given that recent work
has shown that total levels of SLN (active plus inactive) in synovial fluid of patients with
OA are as high as 300 nM (15 ptg/ml) [74], which is within the concentration range tested
here. Given that matrix degradation in OA may progress gradually over many years, it is
interesting that the concentrations of active SLN in the 15 iig/ml range appear quite capable
of causing significant cartilage matrix damage in a much shorter time frame (Fig 2.1). A
likely explanation for this is that a majority of the SLN in OA synovial fluid is most probably
inactive, being either in the proenzyme form or bound to endogenous inhibitors [74,128].
Histological examination (Fig 2.4) showed that initial loss of GAG occurred pri-
marily in the surface regions of the disks, leaving interior regions relatively undegraded.
This observation of a moving front of enzymatic degradation progressing inward from ex-
posed tissue surfaces has been documented previously for the cases of degradation of PG
constituents by Chondroitinase ABC [41] and Streptomyces hyaluronidase [49]. Together,
these results suggest that such high molecular weight enzymes (Mr ~ 20-150 kD), having
limited numbers of spatially accessible cleavage sites within a dense matrix, do not simply
diffuse rapidly into the tissue and degrade it uniformly; rather, they slowly digest their
way into the tissue from the surface with diffusion-reaction, substrate-limited kinetics. In
vivo, it is conceivable that the degradative enzymes in synovial fluid or those produced by
chondrocytes in the superficial zone must first degrade the matrix in the superficial zone
before they can gain access to the interior regions of the tissue. Indeed, Okada et al [95]
showed immunolocalization of SLN in chondrocytes mainly in the superficial and transition
zones of 90% of the human osteoarthritic samples analyzed, in regions where there was
depletion of PG, as revealed in toluidine blue stained sections.
The results shown in Figs 3, 5, and 6 also suggest that SLN has caused significant
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damage to other constituents of the cartilage matrix besides the proteoglycans. Data in
Fig 2.3 show that the addition of SLN to the cartilage culture media causes an increase
in release of type IX collagen fragments into the culture media, as well as an increase in
residual type IX collagen fragments within the tissue. It can be seen (Fig 2.3B) that the
extracts show a broad spectrum of immunoreactive bands with a greater proportion of higher
molecular weight components in the SLN-treated disk extract. In interpreting this finding it
is necessary to consider that type IX collagen molecules are heavily cross-linked to type II
collagen and to each other [135]. Thus, because stromelsyin cleaves the type IX molecule
only at very specific sites, it is expected that a ladder of polymeric fragments will result
from the degradation of the cross-linked matrix protein. Since type IX collagen has been
implicated as a possible crosslinking agent between type II fibrils [30], studies on cartilage
swelling were specifically designed to assess the integrity of the collagen network during
and after SLN treatment. As described by Maroudas [78], the swelling state of cartilage
is determined by a balance between the osmotic pressure of the proteoglycans which tends
to swell the tissue and the restraining tensile forces of the collagen network, which tend to
limit tissue swelling. If the collagen network is compromised, as in OA [78], it is less able
to counteract the osmotic pressure, and the tissue swells.
The addition of SLN to culture media caused an increase in swelling induced by
equilibration in 0.01 M NaC1, up to 25% after three days. The addition of trypsin or
chondroitinase ABC, enzymes known to cause loss of GAG from cartilage, did not alter
swelling compared to untreated controls (Fig 2.5). Taken together these results strongly
suggest that SLN treatment reduced the ability of the collagen network to restrain the
residual swelling pressure of the remaining PG constituents. The data of Fig 2.3 motivate the
hypothesis that degradation of type IX collagen and damage to the type II/type IX complex
contribute to this swelling. Although there is no direct evidence of cleavage by proteinases
other than stromelysin, it should be noted that the possibility of some degradation by
endogenous proteinases, in addition to and perhaps activated by the exogenous stromelysin,
cannot be ruled out when interpreting the results.
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Additional evidence of damage to the cartilage matrix beyond removal of proteo-
glycans is seen in the results of mechanical compression experiments (Fig 2.6A). Previous
studies have shown that neutralization or shielding of proteoglycan fixed charge groups (by
pH or ionic strength alteration) or removal of charge bearing GAG chains by enzymatic
treatment could decrease the modulus or dynamic stiffness of cartilage disks by approxi-
mately 50% [28,41,42]. The results in Fig 2.6A show that exposure to SLN resulted in a
90% loss in equilibrium modulus, a significantly greater loss than that associated with en-
zymes which degrade or remove only proteoglycan constituents. The substantial decrease
in equilibrium modulus suggests that degradation of the cartilage matrix occurred beyond
loss of proteoglycans, possibly including damage to the collagen network.
Dynamic compression studies also showed a large increase in hydraulic permeability
(Fig 2.6B) with time in culture after treatment with 100 /g/ml SLN. At the same time the
GAG content had decreased to 10% of its original value (Fig 2.1). This increase in
hydraulic permeability which accompanied GAG loss is consistent with the previous work
of Maroudas et al, who demonstrated that proteoglycans are the primary source of resistance
to fluid flow in the cartilage matrix [79].
The streaming potential and its dependence on frequency (Fig 2.7B) are of particular
interest regarding the sensitivity of electromechanical measurements to the spatial distri-
bution of enzymatic degradation (Fig 4). The fluid flow that occurs within the cartilage
disk during sinusoidal compression not only contributes to dynamic stiffness (Fig 7A), but
also tends to separate counterions in the interstitial fluid from proteoglycan negative fixed
charge groups [39,40]. The voltage which results from this charge separation is known as
the streaming potential. The measured streaming potential of Fig 2.7B is the total potential
drop across the disk. This potential can be viewed as the the sum of the local potential
drops across incremental layers of the tissue.
At each depth, the local potential drop is proportional to the proteoglycan charge
density and the local fluid velocity relative to the matrix [42]. At high frequency, the
fluid velocity profile is steep, and fluid flow occurs predominantly in a thin region near
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the surface of the disk. At lower frequencies, the velocity profile is less steep and extends
further into the tissue [40]. Thus, most of the streaming potential drop at 1 Hz will occur
within the top most 50-100 ,Im of the 1 mm thick disks and the potential is therefore most
sensitive to the proteoglycan content in the top most layer. At frequencies <0.01 Hz,
however, the potential drops across a much thicker portion of the disk and therefore reflects
the proteoglycan density of deeper as well as surface regions.
Interpreted in this context, the significant decrease in dynamic stiffness and stream-
ing potential with increasing incubation time in SLN is an expected consequence of the
loss of GAG (Fig 2.1). These results are consistent with findings of previous studies of the
effects of enzymatic degradation on cartilage electromechanical behavior [41]. However,
the time dependence of the decrease in potential is highly dependent on frequency, while
the decrease in stiffness is independent of frequency. At 24 hours, the tissue has expe-
rienced approximately 50% loss in GAG content (Fig 1), primarily confined to the outer
100-150 Mm tissue layer (Fig 2.4B). The mean stiffness at 24 hours decreased by 25% at
all frequencies, but was not significantly different from controls. The streaming potential
frequency response was quite different, with negligible loss by 24 hours at 0.01 Hz, but a
significant loss at 1 Hz. This decrease in potential at 1 Hz but not at 0.01 Hz is consistent
with the sensitivity of the streaming potential at higher frequencies to the focal loss of GAG
from the surface region of the disk. Given that the dynamic stiffness had no such frequency
dependence, it is apparent that streaming potential is more sensitive to the initial, focal loss
of proteoglycans from cartilage that results from SLN treatment.
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Chapter III
In Vivo Effects of Stromelysin on the Composition and
Physical Properties of Rabbit Articular Cartilage in the
Presence and Absence of a Synthetic Inhibitor
3.1 Abstract
Objectives. To characterize the effects of intraarticular injection of recombinant human
stromelysin (SLN) on the matrix composition and physical properties of cartilage from
lapine stifle joints and modulation of these effects by the systemic administration of an
n-carboxyalkyl synthetic matrix metalloproteinase inhibitor (MC1).
Methods. Female 6-8 week old New Zealand white rabbits received intraarticular
injection of 100 ,g activated SLN in one stifle joint and buffer in the contralateral control
knee and were sacrificed after one hour. A separate group of animals received intravenous
injection of either 30 mg/kg MC1 or buffer prior to intraarticular injection of SLN. Joints
were dissected and analyzed for proteoglycan (PG) loss into joint fluid, tissue biochemical
composition and histological analysis by toluidine blue or anti-VDIPEN antibody stain-
ing, or frozen for physical property analysis. Disks of femoropatellar groove cartilage
were also harvested from the stifle joint and tested in uniaxially confined compression for
determination of electromechanical and mechanical properties.
Results. Lapine stifle joints which received injection of SLN without systemic
administration of MC1 showed a 13-fold increase in proteoglycan (PG) in synovial fluid.
Cartilage from these joints showed significant decreases in streaming potential at 1 Hz
and electrokinetic coupling coefficient, but no change in equilibrium modulus, dynamic
stiffness, and hydraulic permeability. Treatment with MC 1 resulted in a significant decrease
in loss of PG into joint fluid and elimination of changes in cartilage high frequency streaming
potential and coupling coefficient in joints which received intraarticular injection of SLN.
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Conclusions. The one hour exposure to SLN in vivo resulted in loss of PG and
exposure of the VDIPEN epitope of the aggrecan core protein in a small region of the
tissue near the articular surface. This highly localized degradation resulted in changes in
the electromechanical behavior, but little or no change in mechanical properties. Systemic
administration of MC1 was able to significantly decrease loss of PG into synovial fluid
and prevent even the highly localized tissue degradation and the resultant changes in
electromechanical behavior caused by intraarticular SLN injection.
3.2 Introduction
In healthy joints, articular cartilage serves to distribute loads over bone surfaces and provide
a low friction surface over which bones can move. The porous and highly hydrated matrix
has a sparse population of chondrocytes of approximately 10-100 x 106 cells/ml [117]
responsible for regulating matrix composition and preserving tissue integrity. The cartilage
matrix is composed primarily of hydrated collagen fibrils, highly charged proteoglycan
molecules and other glycoproteins [73,130]. The high tissue water content and electrosta-
tic interactions between proteoglycan fixed charge groups are mainly responsible for the
complex mechanical behavior that characterizes the response of the tissue to physiologic
compressive loads [65].
In osteoarthritis (OA), the combination of altered cartilage matrix composition and
mechanical wear from joint motion can result in erosion of cartilage down to the bone
surface [14]. In its degenerated state, OA cartilage exhibits dramatically different bio-
chemical, physicochemical, mechanical, and electromechanical properties from normal
tissue, including a distinct loss of proteoglycan [19,74,83], marked collagen network fib-
rillation [44,102], increases in tissue hydration [3,78], and loss of compressive stiffness
[3,58]. The role of enzymatic degradation in OA has been studied extensively, but is not
completely understood. It has been suggested [27] that families of enzymes, including
matrix metalloproteinases [20,92,96,100], serine proteases [66], and a novel "aggrecanase"
[110] contribute to cartilage degradation in OA. Given that there are coordinated patterns
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of enzyme expression [23,76], and that many enzymes are synthesized in zymogen form
and require activation by other enzymes [16,119,120], it seems likely that the enzymatic
component of OA involves a "cascade" of activities which work in tandem to degrade the
tissue.
Alterations of biochemical composition and matrix structure which result from en-
zyme activity are manifest in changes in cartilage material properties and physical behavior.
Enzymatic degradation has been shown to result in decreased compressive stiffness [53],
changes in tensile stiffness, strength, and fracture strain [66,112], decreased shear modulus
[55], changes in creep behavior [66,112], and increased indentation displacement [53,66].
In addition, marked decreases in compression-induced streaming potential have been shown
to be particularly sensitive indicators of alterations in matrix proteoglycan composition as-
sociated with enzymatic degradation [41], and in characterizing the spatial distribution
patterns of degradation caused by enzymes such as stromelysin [8].
Stromelysin-1, also known as matrix metalloproteinase 3 (MMP-3), is a neutral
metalloproteinase produced by chondrocytes and synovial fibroblasts [23,76,96], is present
in significant quantities in arthritic tissue and has been implicated in normal matrix turnover,
as well as remodeling and development. Stromelysin degrades several cartilage matrix
components including aggrecan [35,92], link protein [92], and collagen types II, IX, and
XI [134]. It has been found in elevated levels in cartilage and synovial fluid in patients
with degenerative OA [74,96], as well as in animal models of OA [20,100]. Elevated levels
of mRNA expression have likewise been detected in patients with knee joint injury [74]
and heat shock [123], respectively. There is also evidence of elevated stromelysin gene
expression in early stages of soft tissue development [12] as well as immunolocalization of
stromelysin in cartilage growth plate [13]. In addition, stromelysin is capable of radically
altering the composition and physical properties of cartilage explants [8].
Although studies have focused on the effects of stromelysin on isolated cartilage
matrix constituents or on cartilage explants in vitro, less attention has been given to the
action of stromelysin on intact cartilage in vivo. Therefore, the primary objectives of this
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work were (1) to determine the effects of intraarticular injection of stromelysin on the
composition of rabbit stifle joint cartilage, (2) to correlate alterations in cartilage matrix
composition with changes in physical properties, and (3) to evaluate modulation of these
effects by systemic administration of a synthetic matrix metalloproteinase inhibitor.
3.3 Materials and Methods
3.3.1 In Vivo Treatment
In one series of experiments, 6 female New Zealand white rabbits from 6-8 weeks in age
(2-3 kg) received intraarticular (IA) injection into one stifle joint of 100 1Lg recombinant
human stromelysin (SLN) in 1.0 ml phosphate buffered saline (PBS), while the contralat-
eral joint was injected with PBS alone. In another series of experiments a group of 8
rabbits received intravenous (IV) injection of 30 mg/kg of a -500 Da synthetic matrix
metalloproteinase inhibitor (MC1) N-[ 1 (R)-carboxy-ethyl]-a-(S)-(2-phenyl-ethyl)glycine-
(L)-leucine, N-phenylamide [22], in a buffer composed of 70% PBS, 15% dimethylsulfoxide
and 15% Cremaphore EL (polyethylene glycerol tricinoleate, BASF, Parsippany, NJ) 30
minutes prior to IA injection of SLN. A second group of 8 animals received IV injection
of buffer alone, 30 minutes prior to IA injection of SLN. One hour after injection with
SLN, all rabbits were sacrificed and both joints were lavaged with two 1.0 ml aliquots of of
PBS. After sacrifice, all groups of joints were frozen and stored for characterization of joint
cartilage physical properties. Separately, animals were treated identically to the 3 treatment
groups described above and their joints were subsequently harvested for histological exam-
ination. In a separate series of experiments, 7 groups of 4 animals received IV injection of
10 mg/kg MCi. Animals were sacrificed at selected times after IV injection and joint fluids
were lavaged and assayed for MC 1 content.
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3.3.2 Histology
Freshly dissected samples of cartilage were embedded in O. C. T. compound (Tissue-
Tek) and frozen in liquid nitrogen. Six pm cryosections were cut through the cartilage
samples, fixed in Nakane fixative [84], and permeabilized with 0.1% Triton X-100 in PBS
(Gibco). To assess GAG content, sections were stained using toluidine blue [45]. To
monitor accumulation of the rabbit aggrecan neoepitope FMDIPEN [6], and anti-VDIPEN
antibody was used [72]. This antibody specifically recognizes the C-terminal sequence
(FVDIPEN341) of the stromelysin-generated hyaluronan binding region of human aggrecan
[72]. It has also been shown to react with the corresponding neoepitope in rabbit aggrecan,
FMDIPEN [6]. Bound anti-VDIPEN IgG was detected by immunoperoxidase microscopy
using the ABC technique (Elite kit: Vector Laboratories, Inc., Burlingame, CA). The
peroxidase reaction product was developed using a glucose oxidase/DAB/nickel method
[115].
3.3.3 Physical Properties
Intact lapine stifle joint were isolated after sacrifice and stored at -70 C for up to 3 months.
For physical property tests. The stifle joints were dissected to expose the femoropatellar
groove, and up to 3 bone/cartilage cylinders were harvested from each joint using a 3 mm
dermal punch (Miltex Instruments, Lake Success, NY). Cartilage was separated from the
bone immediately prior to mechanical compression, using a scalpel to cut approximately
plane parallel cartilage disks. Each disk was immediately mounted in an electrically insulat-
ing cylindrical confining chamber described previously [41]. This chamber was mounted in
a servo-controlled Dynastat mechanical spectrometer (IMASS, Hingham, MA) interfaced
to a computer and frequency generator (Model 5100, Rockland Systems, West Nyack, NY).
Cartilage samples were equilibrated in 0.15 M phosphate buffered saline (PBS)(Gibco,
Grand Island, NY) at pH 7.4 containing 100 U/ml penicillen G and 100 gg/ml streptomycin
at room temperature. Samples were compressed between a porous polyethylene platen and
a 6.35 mm Ag/AgCl pellet electrode (Annex Research, Costa Mesa, CA) mounted in the
Section 3.3
-65-
base of the chamber. An identical electrode was mounted in the surrounding PBS bath as
a reference electrode. Cartilage disks were mounted in the chamber with the top of the
disk (the articular surface) in contact with the porous platen and bottom of the plug (the
cartilage/bone interface) in contact with the chamber electrode, preserving the anatomical
orientation of the tissue relative to the testing chamber.
After mounting each disk in the confined compression chamber, individually, the
distance between the porous platen and bottom electrode was decreased until a (e,,5-10 g)
signal was detected by the load cell, and this distance was taken to be the sample thickness.
Subsequently, each cartilage disk was compressed by sequential increments of 0.5-1.0%
static strain to a maximum of 20% total strain. After stress relaxation, the equilibrium
stress resulting from each increment in imposed static strain in the 15-20% range was
detected by the Dynastat load cell and recorded by the computer. The equilibrium confined
compression modulus was obtained by a best fit linear regression of these equilibrium
stress-strain data. At a given static offset strain, sinusoidal strains of <1% amplitude
were superimposed the stating strain in frequencies ranging from 0.01 Hz to 1 Hz. The
resultant oscillatory loads were detected by the Dynastat load cell and the oscillatory
streaming potentials were measured by the chamber electrodes which were connected to a
high-impedance Universal Amplifier, Model 11-4113-02 (Gould, Inc., Cleveland OH). The
load and streaming potential signals were recorded simultaneously by the computer. The
total time for equilibration and testing one sample by this procedure was <1 hour. The
dynamic stiffness was obtained by normalizing the measured load to the applied strain and
sample area, while the amplitude of the streaming potential was normalized to the applied
dynamic strain. Dynamic stiffness, streaming potential, and equilibrium modulus data were
used with the method of Frank and Grodzinsky [40] to calculate an effective electrokinetic
coupling coefficient (a parameter which relates the streaming potential to load developed
in the tissue) and an effective hydraulic permeability (a parameter which indicates the ease
with which fluid moves through the cartilage matrix). In all tests, the amplitude of the
applied strain was chosen to be small enough to elicit a linear response from the sample
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[39,40] and the total harmonic distortion in the measured load was < 10% for all samples
tested. The porous platen remained in contact with the samples at all times during the
testing cycle.
3.3.4 Biochemical Analyses
After physical property tests, cartilage disks were frozen at -20 oC, lyophilized, and digested
with 1 ml of 125 zg/ml papain digestion solution (Sigma, St. Louis, MO) as described pre-
viously [105]. Small (201 l) portions of the digests from each disk were assayed for
sulfated GAG content by quantification of their reaction with 2 ml of dimethylmethylene
blue (DMB) dye solution in polystyrene cuvets (VWR, Boston, MA) by spectrophoto-
metric measurements (Model 3AB, Perkin Elmer, Norwalk, CT) [34], using whale/shark
chondroitin sulfate (Sigma) as the standard.
Synovial fluid lavages taken immediately after sacrifice were assayed for MC1
content by mass spectrometry and for GAG content by the DMB dye binding assay as
previously described [34].
3.4 Results
3.4.1 Biochemical Analysis
Analysis of joint fluid lavages revealed that synovial fluid MC1 content peaked at >6 Ipg
at 30 minutes after IV injection of 10 mg/kg MC1 and remained at levels >0.3 /tg for 5
hours after IV injection (Fig 3.1). IA injection of 2.0 ml of PBS yields 2.3 + 0.3 ml of
fluid, implying a joint fluid volume of approximately 300 /l. Without IV MC1, average
GAG content of disks from SLN treated joints was 88% that of disks from control, which
had 0.053 ± 0.010 (g GAG)/(g tissue wet weight). With IV MC1, GAG content of treated
disks was 90% of disks from control joints (Fig 3.2). In neither case was the difference
statistically significant. Measured levels of GAG in joint fluids from SLN treated joints
(with no IV injection) were 280 ± 15 Ag GAG/joint, with approximately 4 mg of GAG from
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harvested joint cartilage. In the absence of IV MC 1, joint fluid PG levels from SLN treated
joints were 13 times higher than contralateral controls, and with IV injection of MC1, there
was a 70% reduction in joint fluid PG levels (Fig 3.2).
3.4.2 Histology
Examination of sections of femoropatellar groove cartilage revealed a marked of decrease
in Toluidine Blue staining (Fig 3.3A) and pronounced staining of anti-VDIPEN (Fig 3.3D)
in regions of the tissue near the articular surface in joints injected with 100 pg/ml SLN
in the absence of IV MC1. Control joints showed minimal or no loss in Toluidine Blue
staining (Fig 3.3B) and little presence of anti-VDIPEN antibody (Fig 3.3E). Cartilage from
rabbits which received IV injections of 30 mg/kg MC1 showed a marked decrease in loss
of Toluidine Blue staining (Fig 3.3C) and presence of anti-VDIPEN antibody (Fig 3.3F)
in SLN injected joints, as compared to cartilage from animals which received blank IV
injections.
3.4.3 Physical Properties
Using the Dynastat load cell to ensure that both platen surfaces were in contact with the
specimen, the effective thickness of cartilage disks harvested from rabbit joints was deter-
mined to be 486 + 62 Am and 491 + 106 Am for control and SLN-treatedjoints, respectively.
Treatment with IV MC1 did not significantly alter the measured disk thickness. For rab-
bits which did not receive IV injection, the streaming potential ranged from 7.8 pV/% at
0.01 Hz to 21.8 [V/% at 1 Hz for cartilage from control joints and from 4.0 1LV/% at 0.01 Hz
to 5.5 pV/% at 1 Hz from cartilage from joints which received IA injection of 100 ,g SLN
(Fig 3.4A). Values of dynamic stiffness ranged from 4.4 MPa at 0.01 Hz to 1.38 MPa at 1 Hz
and from 3.9 MPa at 0.01 Hz to 1.24 MPa at 1 Hz for cartilage disks from control and SLN
treated joints respectively (Fig 3.4B).
From stress-strain data measured in the range of 15-20% static strain, the equilib-
rium confined compression modulus of cartilage disks from control joints was 219 kPa.
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Using modulus, streaming potential, and dynamic stiffness data, the hydraulic perme-
ability and electrokinetic coupling coefficient were calculated to be 1.36 x 10-14 m2/Pa-s
and 0.98x 10- 9 V/Pa respectively. By comparison, indentation studies performed on
femoropatellar cartilage from skeletally mature New Zealand White rabbits [5] gave values
of 510kPa for equilibrium modulus and 3.38 x 10-15 m2/Pa-s for hydraulic permeability,
with cartilage thickness of 200 tm. The material properties of cartilage disks from control
joints in animals which received either IV injection of buffer did not differ from those which
received MC 1 and were not significantly different from those of samples from animals which
did not receive IV injections.
The measured values of streaming potential and dynamic stiffness at 1 Hz, coupling
coefficient, equilibrium modulus, and hydraulic permeability were normalized to values for
control disks obtained from animals given no IV injection (Fig 3.5) and IV injection of buffer
(Fig 6A) or 30 mg/kg MC1 (Fig 3.6B). For animals given no IV injection, dynamic stiffness
at 1 Hz, equilibrium modulus, and hydraulic permeability of cartilage from SLN injected
joints did not differ significantly from controls, while streaming potential at 1 Hz was 25%
of control and coupling coefficient was 51% of control (p < 0.02 and 0.05 respectively (Fig
3.5)). For SLN treated cartilage, streaming potential was significantly different (p < 0.05)
from control at all frequencies > 0.1 Hz. Results from experiments with rabbits given IV
buffer (Fig 3.6A) were similar to those with no IV (Fig 3.5), with no observed difference
in dynamic stiffness at 1 Hz, equilibrium modulus, and hydraulic permeability between
control and SLN injected joints, but significant differences in streaming potential at 1 Hz
and coupling coefficient. The streaming potential of cartilage from SLN treated joints was
significantly less that from contralateral controls for all testing frequencies > 0.1 Hz (Fig
3.4). For animals which received 30 mg/kg MC 1, there was again no difference in dynamic
stiffness at 1 Hz, equilibrium modulus, and hydraulic permeability. In addition, streaming
potential at 1 Hz and coupling coefficient of treated cartilage were 91% and 84% of control
values, and this difference was not statistically significant (Fig 3.6B).
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Figure 3.1: Amount of synthetic matrix metalloproteinase inhibitor (MC 1) in synovial fluid
lavage vs. time after intravenous injection of 10 mg/kg MC (n =4 ± SEM). For 2 x 1 ml
injections of PBS, 2.3 ± 0.3 ml was recovered, giving an average joint fluid volume of
0.3 ml.
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Figure 3.2: A: GAG content of mechanically tested cartilage disks from the femoropatellar
grooves of 8 rabbits which received intravenous injection of 30 mg/kg MC1 and 8 rabbits
which received IV injections of buffer with no MC 1. Disk GAG concentrations (per tissue
wet weight) from SLN-injected joints were normalized to GAG content of disks from
contralateral control joint. B: Normalized GAG content of joint fluid lavages from lapine
stifle joints from animals which received intravenous injection of 30 mg/kg MC 1 or buffer
alone.
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Figure 3.3: Toluidine blue staining of femoropatellar groove cartilage from stifle joints
which received intraarticular injection of SLN (A), buffer (C), or SLN with intravenous MC 1
(E). Immunostaining of FMDIPEN neoepitope in cartilage from SLN injected joints (B),
buffer injected joints (D), or SLN injected joints from rabbits that received an intravenous
injection of MC1 (F).
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Figure 3.4: Frequency response of measured streaming potential (A) and dynamic stiffness
(B) of cartilage disks from a group of 6 lapine stifle joints which received intraarticular
injection of 100 j/g SLN and contralateral control joints (n = 6 ± SEM). Section 3.4
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Figure 3.5: Normalized streaming potential at 1 Hz, electrokinetic coupling coefficient,
dynamic stiffness at 1 Hz, equilibrium modulus, and hydraulic permeability of cartilage
disks from lapine stifle joints which received intraarticular injection of 100 gg SLN and
from contralateral control joints. (The dynamic properties of these disks are shown in Fig
3.4.)
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Figure 3.6: A: Normalized streaming potential at 1 Hz, electrokinetic coupling coefficient,
dynamic stiffness at 1 Hz, equilibrium modulus, and hydraulic permeability of cartilage
disks from a group of 8 animals which received intravenous injection of buffer. Stifle joints
which received intraarticular injection of 100 pg SLN are compared to contralateral control
joints. B: Normalized streaming potential at 1 Hz, electrokinetic coupling coefficient,
dynamic stiffness at 1 Hz, equilibrium modulus, and hydraulic permeability of cartilage
disks from a group of 8 animals which received intravenous injection of MC 1. Stifle joints
which received intraarticular injection of 100 pg SLN are compared to contralateral control
joints. (The GAG content of cartilage and synovial fluid from these joints is shown in Fig
3.2.)
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3.5 Discussion
All indicators of cartilage degradation induced by IA injection of 100 p/g SLN were sig-
nificantly inhibited by IV treatment with 30 mg/kg MC1. The loss of PG fragments from
cartilage to the synovial fluid was significantly decreased by the administration of MC1
prior to IA injection of SLN (Fig 3.2). The loss of Toluidine Blue staining (Fig 3.3A) and
the presence of anti-VDIPEN antibody (Fig 3.3D) near the articular surface which resulted
from IA injection of SLN did not occur following administration of IV MC1 (Fig 3.3C,3F).
High frequency streaming potential and electrokinetic coupling coefficient, which were
both dramatically decreased (Fig 3.6A) were similar to control values with IV injection of
MC1 prior to IA injection of SLN (Fig 3.6B). Taken together these data seem to indicate that
MC1 was quite effective at inhibiting SLN inside the joint. While it is unclear if inhibition
occurred in the tissue itself, it seems likely that MC1 was able to inhibit SLN while it was
still in the synovial fluid, and therefore prevent degradation and the resultant changes in the
physical properties of the joint cartilage.
For the 1 hour duration of the in vivo experiments, levels of MC1 in synovial fluids
were seen to be in relative abundance compared to levels of IA injected SLN. At 75 minutes
after IV injection of 10 mg/kg MC1, which corresponds to the time at which the rabbits
were sacrificed, levels of MC1 in synovial fluid were in excess of 3.75 fg (Fig 3.1). Given
that the volume of joint fluid was measured to be 300 pl, the effective MC 1 concentration
was approximately 25 /iM. Similarly, injection of 100 ,ag of SLN (-50 kDa) into the joint
gave an effective SLN concentration of approximately 6.6 pM, and thus a 4-fold molar
excess of MC 1. For experiments involving IV a 30 mg/kg dose of MC1 (Fig 3.6B), it likely
that the molar ratio of MC1 to SLN was even greater than 4 to 1.
Measurements of GAG content of joint fluid and tissue indicate that while there was
loss of GAG to the synovial fluid due to IA injection of SLN, the majority of the GAG
remains within the cartilage (Fig 3.2). Comparison of SLN treated and untreated joints
shows that GAG content of mechanically characterized cartilage disks from SLN treated
joints was ~90% of controls. This is consistent with joint fluid data which show a loss of
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290 pg of PG from SLN treated joints, corresponding to < 10% of the 4 mg of PG measured
in the joint cartilage. The relatively small amount of PG loss seen here is consistent with
the 1 hour duration of the experiment. In vitro studies [8] have also demonstrated that the
time required to remove most of the PG in the joint cartilage would be on the order of days
for the SLN concentrations used here.
Histological examination revealed the marked loss of toluidine blue staining near
the articular surface (Fig 3.3A), and intense staining for VDIPEN neoepitope in the same
region (Fig 3.3D), suggesting that the surface loss of PG from the cartilage was due to
cleavage of aggrecan by SLN. This is also similar to observations in vitro which indicated
that cartilage explants cultured in media containing SLN [8] or other enzymes [41,49]
were initially degraded at the tissue surface when the relatively high molecular weight
enzymes had a limited number of spatially accessible cleavage sites and were not able to
penetrate the dense cartilage matrix until it had been degraded. Thus, for the short times
(- 1 hour) relevant to these experiments, SLN injected into the joint did not appear to have
access to deeper tissue regions and preferentially degraded a thin layer of cartilage near the
articular surface. This is of particular interest, given that other studies have shown that SLN
production may be localized to the superficial zones of cartilage [96] or the synovium [20]
in osteoarthritis.
The value of equilibrium modulus reported here (219 kPa) is 2-3 times lower and
hydraulic permeability (1.36 x 10-14 m2/Pa.s) and measured cartilage thickness (486 pm)
are 2-3 times higher than data reported by Athanasiou et al [5]. Given that the cartilage
from the skeletally mature animals examined by Athanasiou et al is likely to be stiffer, less
thick, and denser (and consequently less permeable) than the cartilage from the 6-8 week
old rabbits used in this study, these differences seem reasonable.
The frequency response of the streaming potential and dynamic stiffness (Fig 3.4)
are typical of the poroelastic material behavior exhibited by articular cartilage [40]. The
frequency behavior of the streaming potential and dynamic stiffness of cartilage disks from
SLN injected joints are also consistent with the biochemical (Fig 3.2) and histological data
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(Fig 3.4). Since the degradation caused by injection of SLN is confined to regions near the
articular surface, the bulk of the tissue remained undegraded. Thus, the mechanical integrity
of bulk of the tissue, as reflected in properties such as equilibrium and dynamic stiffness,
was not appreciably altered. However, the streaming potential, which is highly dependent
on localized fluid flows [8,40], is much more sensitive to such focal degradation. In high
frequency tests, fluid flow occurs mainly in a narrow region near the tissue surface, and thus
the streaming potential is significantly decreased by the loss of PG near the tissue surface
[8,41]. At lower testing frequencies, when fluid exchange occurs throughout a greater
portion of the tissue, the streaming potential reflects the bulk composition of the tissue
which has not change significantly. Thus, the difference in streaming potential between
cartilage from SLN treated and control joints is greatest at high frequency and decreases as
the frequency is lowered (Fig 3.4).
When analyzed together, the spectrum of properties measured suggest that the
electromechanical measurements are more sensitive than the purely mechanical measure-
ments to the focal degradation caused by IA injection of SLN with either no IV injection
(Fig 3.5) or IV injection of control buffer (Fig 3.6A). These electromechanical properties
(streaming potential and electrokinetic coupling coefficient) which reflect the streaming
potential behavior across all frequencies, are affected by local distributions of fixed charge,
and therefore PG, while the mechanical properties (dynamic stiffness, equilibrium modulus
and hydraulic permeability) are less sensitive to surface alterations in matrix composition.
These data are also consistent with studies on degradation of cartilage explants by SLN in
vitro [8] in which short term exposure resulted in significant changes in streaming potential
at high frequency, while mechanical properties such as dynamic stiffness were not affected.
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Chapter IV
Activation and Inhibition of Endogenous Matrix
Metalloproteinases in Articular Cartilage: Effects on
Composition and Physical Properties
4.1 Abstract
Bovine cartilage explants were cultured in the presence of 1 mM 4-aminophenylmercuric
acetate (APMA) to activate endogenous matrix metalloproteinases (MMPs) and changes in
biochemical, biormechanical, and physicochemical properties were assessed. Additionally,
graded levels of either recombinant human tissue inhibitor of metalloproteinases- 1 (TIMP)
or a synthetic metalloproteinase inhibitor (MC1) were used to inhibit degradation induced
by APMA. Treatment with APMA resulted in as much as 80% loss in tissue proteoglycan
content and a >3-fold increase in the presence of denatured type II collagen as determined
by the presence of CB 11B peptide after 3 days in culture. Physicochemical studies revealed
that APMA treatment resulted in a significant increase in tissue swelling, consistent with
damage to the collagen network. Activation of MMPs by APMA also resulted in >80%
decrease in equilibrium modulus, dynamic stiffness, and streaming potential and >50%
decrease in electrokinetic coupling coefficient. The addition of 4 AM, 400 nM and 40 nM
TIMP inhibited PG loss by 95%, 50%, and 20%, respectively and all doses effectively
inhibited swelling response. The addition of 4 pM and 400 nM MC1 inhibited PG loss
by 95% while 40 nM MC1 inhibited PG loss by 60%, and all doses effectively inhibited
tissue swelling. Cartilage disks treated with 4 /M TIMP and 1 mM APMA had signif-
icantly greater streaming potential, electrokinetic coupling coefficient, dynamic stiffness
and equilibrium modulus than disks treated with APMA alone.
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4.2 Introduction
Degradation of cartilage extracellular matrix by proteinases is a prominent feature of os-
teoarthritis. Although several classes of proteinases are found in mammalian cells, recently
much attention has been paid to the role of matrix metalloproteinases (MMPs) in cartilage
destruction in the process of OA [90,127].
MMPs are are a family of at least 12 enzymes which are divided into three main
classes: collagenases, gelatinases, and stromelysins. Gelatinases are not thought to play a
major role in degradation of cartilage matrix; however, interstitial collagenase (MMP-1) is
known to degrade collagen types II and X [127], while stromelysin-1 (MMP-3) is known
to degrade aggrecan [35], link protein [92], and collagen types II, IX, X, and XI [134].
Both collagenase and stromelysin are produced by chondrocytes and synovial fibroblasts
[23,76,96]. These MMPs are present in elevated levels in cartilage and synovial fluid of
patients with degenerative OA [74,96,98], as well as in animal models [20,81,100]. Elevated
levels have likewise been detected in cases of knee joint injury [74] and heat shock [123].
There is also evidence of MMP gene expression in early stages of soft tissue development
[.12] as well as immunolocalization of MMPs in cartilage growth plate [13].
Members of the MMP family are synthesized and secreted in a latent zymogen form
which requires activation by proteolytic cleavage of a peptide sequence at the N-terminus
of the molecule [127]. This activation can take place from cleavage by plasmin, trypsin,
or organo-mercurial compounds such as 4-aminophenylmercuric acetate (APMA). Nagase
et al demonstrated that in the presence of APMA, native prostromelysin or procollagenase
will undergo a conformational change which results in the production of an intermediate
which is then self-catalyzed to produce an active form of the enzyme [89]. Previously,
APMA has been used to activate latent MMPs produced by cartilage after treatment with
IL-1, [100] or in animal models of arthritis [99].
There are several naturally occurring inhibitors of MMP activity including a2-
rnacroglobulin (a2-M) and tissue inhibitor of metalloproteinases-1 and -2 (TIMP-1 and
TIMP-2). a 2-M is a large molecule (,-750 kDa) produced by the liver and found in synovial
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fluid. It inhibits MMPs by presenting a peptide sequence which is cleaved by the enzyme,
then engulfing the enzyme and restricting its access to other substrates. Both TIMPs are
also large (r,,28 and 22 kDa, respectively) and are produced by chondrocytes and synovial
fibroblasts. The TIMPs inhibit MMPs by binding tightly to the MMP active site. In healthy
joints, there is as much as a two-fold molar excess of TIMP compared to stromelysin and
collagenase in synovial fluid [74], while in cases of OA enzyme concentrations have
been seen to exceed levels of native TIMPs [74,81]. Efforts to use TIMP to inhibit
degradation proteoglycan induced by IL- la in cartilage explants have not been successful
[1], presumably due to the inability such a large protein to penetrate the dense cartilage
matrix.
Alterations of biochemical composition and matrix structure which result from en-
zyme activity are manifest in changes in cartilage material properties and physical behavior.
Enzymatic degradation has been shown to result in decreased compressive stiffness [53],
changes in tensile stiffness, strength, and fracture strain [66,112], decreased shear modulus
[55], changes in creep behavior [66,112], and increased indentation displacement [53,66].
In addition, marked decreases in compression-induced streaming potential have been shown
to be particularly sensitive indicators of alterations in matrix proteoglycan composition as-
sociated with enzymatic degradation [41], and in characterizing the spatial distribution
patterns of degradation caused by large enzymes such as stromelysin [7-9].
Previous studies have established the effects of MMPs on isolated cartilage matrix
components in solution. In addition, there have been many studies on degradation of intact
cartilage induced by IL-1 and retinoic acid, but the mechanism by which the degradation
occurs in these systems is not completely resolved. Given that significant quantities of
MMPs have been detected even in undegraded tissue, activation of these native enzymes
has the potential to dramatically alter the cartilage matrix. Therefore, the primary objectives
of this study were to (1) determine the effects of APMA-activation of endogenous MMPs
on the biochemical, physicochemical, and physical properties of cartilage explants and
(2) evaluate the ability of TIMP-1 and a low molecular weight MMP inhibitor to prevent
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APMA-induced cartilage degradation.
4.3 Materials and Methods
4.3.1 Cartilage Explant and Culture
Saddle sections of 1-2 week old calves were obtained from a local abbatoir (A. Arena,
Hopkington, MA) within four hours of slaughter. The femoropatellar groove was isolated,
and 1 mm thick cartilage x 3 mm diameter disks were harvested using a a sledge microtome
(Model 860, American Optical, Buffalo, NY) and dermal punch (Miltex Instruments, Lake
Success, NY) as described previously [ 105]. Cartilage disks were incubated in groups of 4 in
24-well culture dishes (Costar, Cambridge, MA) in 1 ml DMEM (Gibco, Grand Island, NY)
containing 100 U/ml penicillin G and 100 ig/ml streptomycin (Gibco) for approximately
16 hours at 37 oC in a 5% CO 2 atmosphere.
Groups of 4 disks were then placed in 1 ml DMEM in the presence or absence
of 1 mM 4-aminophenylmercuric acetate (APMA) (Sigma, St. Louis, MO) to activate
endogenous MMPs, and removed from culture at times up to 72 hours. In addition, selected
groups of samples which received APMA treatment were also cultured in the presence of
MMP inhibitors or a cocktail of proteinase inhibitors which did not inhibit MMPs. Separate
groups of plugs were treated with 100 p/g/ml recombinant human stromelysin as described
previously [8]. Recombinant human tissue inhibitor of metalloproteinases-1 in 25 mM Tris
HCl, 10 mM CaC12, and 0.01% NaN3 was concentrated to -,300 pg/ml using a Centricon
10 ultrafiltration membrane (Amicon, Inc., Beverly, MA) as described previously [70] and
diluted into media for tissue culture experiments.
To study inhibition of matrix degradation, plugs were incubated with recombi-
nant human tissue inhibitor of metalloproteinases-1 (TIMP) [70] or a synthetic MMP in-
hibitor N-[ 1 (R)-carboxy-ethyl]-a-(S)-(2-phenyl-ethyl)glycine-(L)-leucine, N-phenylamide
(MC1) [22] in concentrations ranging from 40 nM to 4 pjM, simultaneous to APMA treat-
ment. To prevent degradation from other matrix proteinases, the following cocktail was
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used: 10 mM benzamidine hydrochloride (Sigma) to inhibit trypsin-like activity, 10mM
N-ethylmaleimide (Sigma) to inhibit sulfylhydry-dependent proteinases, 1 mM phenyl-
imethanesulfonyl fluoride (Sigma) to inhibit serine proteinases such as cathepsin B, 1 pM
pepstatin (Calbiochem) to inhibit acid proteinases including cathepsin D. Upon removal
from culture, plugs were allocated for biochemical, physicochemical and biomechanical
analyses. Separate groups of plugs were cultured in DMEM which contained 10 /Ci/ml
[35S]sulfate and [:3H]proline (New England Nuclear, Boston, MA) for 24 hours, then washed
3 times in phosphate buffered saline at 4 C to assess levels of tissue biosynthetic activity.
4.3.2 Biochemical Analyses
Disks allocated for biochemical analysis were frozen at -20 C, lyophilized, and digested
with 1 ml of 125 /ig/ml papain digestion solution (Sigma) as described previously [105].
20 gl portions of digests and culture media were assayed for sulfated GAG by reaction with
2 ml of dimethylmethylene blue dye solution in polystyrene cuvets (VWR, Boston, MA)
and spectrophotometry (Model A3B, Perkin Elmer, Norwalk, CT) [34] using whale/shark
chondroitin sulfate (Sigma) as the standard.
In addition, 100 pl portions of the digest were analyzed for radioactivity by mix-
ing with 2 ml Ecolume scintillation fluid (ICN Biochemicals, Irvine, CA) and measuring
3H-cpm and 35S-cpm in a liquid scintillation counter (RackBeta 1211, LKB, Turku, Fin-
land), with corrections for spillover and dilution quenching. Radiolabel incorporation was
normalized to sample DNA content as measured by reaction of 100 [l of digest with 2 ml
Hoechst 33258 dye solution (Hoechst-Celanese, Summit, NJ) in an acrylic cuvet (VWR)
and fluorometry (SPF-500C Spectrofluorometer, SLN Instruments, Dowington, PA), using
calf thymus DNA as a standard [69].
Portions of tissue digests were assayed for the presence of cyanogen bromide peptide
11 of the ac(II) chain (al(II)-CB1 B peptide) of type II collagen in the laboratory of Dr.
A Robin Poole. Mouse antiserum purified against a (II)-CB 11B peptide was produced as
described previously [60]. Serum samples were tested for reactivity against heat denatured
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type II collagen, but showed no reactivity against hydroxylysine residues. The amount
of al(II)-CB 1 lB epitope in tissue digests was quantified by competitive enzyme linked
immunosorpent assay (ELISA) on a microtiter plate using this antiserum. Hydroxyproline
content of portions of tissue digests was evaluated by colorimetric assay as described
previously [116].
4.3.3 Swelling Studies
The protocol for swelling studies was motivated by the technique used by Maroudas [78]
to compare the swelling of normal and osteoarthritic cartilage. Disks removed from culture
medium were patted briefly with a paper towel to remove surface water, and wet weights
were measured (AE 163 Balance, Mettler Instrument Corp, Hightstown, NJ). Disks were
then twice reequilibrated in 1 ml of hypotonic saline solution (0.01 M NaCl at pH 7.0)
for 1 hour at room temperature. Surface water was again removed and wet weights were
measured. Following wet weight measurements, disks were lyophilized, and dry weights
were recorded. Previously, it has been shown that this method is sensitive to damage to the
cartilage matrix collagens, but is not sensitive to changes in tissue proteoglycan content [8].
4.3.4 Biomechanical and Electromechanical Evaluation
Cartilage disks were placed in an electrically insulating poly(methylmethacrylate) cylindri-
cal confining chamber, similar to that used by Frank et al [41]. The chamber was mounted in
a servo-controlled Dynastat mechanical spectrometer (IMASS, Hingham, MA) which was
interfaced to a computer and frequency generator (Model 5100, Rockland Systems, West
Nyack, NY). Samples were equilibrated in 0.15 M phosphate buffered saline (PBS)(Gibco)
at pH 7.4 containing 100 U/ml penicillin G and 100 pg/ml streptomycin at room tempera-
ture. Disks were subjected to confined compression between a porous polyethylene platen
and a 6.35 mm Ag/AgCl pellet electrode (Annex Research, Costa Mesa, CA) mounted at
the base of the chamber. An identical electrode was mounted in the surrounding PBS bath.
Disks were first compressed by sequential increments of 0.5-1.5% strain, up to a
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maximum of 20% total strain. After stress relaxation, the equilibrium stress correspond-
ing to each increment of static strain was detected with the load cell of the Dynastat and
recorded on the computer. The resultant equilibrium stress was plotted against applied
strain and the slope of the best fit linear regression curve gave the equilibrium confined
compression modulus. At a given static offset strain, sinusoidal strains of <1% amplitude
were superimposed on the static strain at frequencies ranging from 0.01 Hz to 1 Hz. The
resultant oscillatory, load was detected by the load cell and the oscillatory streaming po-
tential was detected by the chamber electrodes which were connected to a high-impedance
Universal Amplifier, Model 11-4113-02 (Gould, Inc., Cleveland, OH). Load and streaming
potential were simultaneously recorded by the computer. The amplitude of the dynamic
load was normalized to disk area and to the amplitude of the applied strain to give dynamic
stiffness, while the amplitude of the streaming potential was normalized to the amplitude
of the applied strain [39,40]. Equilibrium modulus and dynamic stiffness data were used
in combination with the method of Frank and Grodzinsky [40] to calculate the effective
hydraulic permeability of the tissue specimen. In all tests the amplitude of the applied
strain was chosen to be small enough to elicit a linear mechanical response from the sample
139,40] (i. e. the total harmonic distortion in the measured load was <10%). The porous
Iplaten remained !in contact with the sample at all times during the testing cycle.
4.4 Results
4.4.1 Biochemical Analyses
Treatment with 1 mM APMA resulted in significant loss of proteoglycan (PG) fragments
from cartilage disks after 12 hours, with losses ranging from >50% (Fig 4.1) to >80% (Fig
4.2) after 3 days in culture. GAG content of control samples at the beginning of the culture
was 652 ± 86 gg GAG/cartilage disk. Control samples or those treated only with 4 PM
TIMP showed < 1]0% PG loss after 72 hours of treatment. Disks treated with 1 mM APMA
with a cocktail of non-MMP proteinase inhibitors showed loss of PG similar to that of
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disks treated with APMA alone (Fig 4.1). Exposure of cartilage disks to 1 mM APMA with
simultaneous treatment with graded levels of TIMP resulted in a dose dependent inhibition
of APMA-induced PG loss (Fig 4.2A). A 4 AM dose of TIMP resulted in >90% inhibition of
PG loss, while 400 nM and 40 nM doses yielded r50% and r20% inhibition respectively.
Similar treatment with MC1 resulted in >95% inhibition of PG loss for both the 4 AM and
400 nM doses of MC1 and >60% inhibition at 40 nM (Fig 4.2B).
Incorporation of radiolabeled macromolecules containing [35S]sulfate and
[3H]proline into the cartilage matrix matrix was significantly suppressed by the addition of
APMA into the culture media. Control disks incorporated 4063 + 548 [3H] cpm//lg DNA
compared to 79 ± 15[3H] cpm//lg DNA for disks which were cultured with 1 mM APMA
for 24 hours. In addition during 1 day in culture control disks incorporated 5677 ± 472
[35S] cpm//g DNA, while disks treated with APMA incorporated 57 ± 7.6 [35S] cpm//g
DNA. Both [3H]proline and [35S]sulfate data indicate that APMA-treated cartilage disks
were biosynthetically inactive. Data are given as mean ± standard deviation for n = 4 disks.
APMA treatment also resulted in increased unwinding of type II collagen (Fig 4.3),
as determined by the appearance of the collagen CB 11B epitope. The amount of type II
collagen with accessible CB 11B peptide was normalized to total collagen content to give
the percentage of denatured type II collagen. In control samples after 3 days in culture,
r2% of the type II collagen was denatured, as compared to -7% in samples treated with
1 mM APMA. The amount of denatured collagen in disks treated with 100 /g/ml SLN was
similar to that of control disks.
4.4.2 Swelling Studies
Swelling of tissue incubated in the presence of 1 mM APMA, 1 mM APMA with 40 nM
TIMP, and 1 mM APMA with 40 nM MC1 was quantified as the ratio of plug wet weight
in 0.01 M NaCl to wet weight in DMEM (Fig 4.4). Untreated plugs swelled by 2-3% in
hypotonic saline at all time points, while those treated with 1 mM APMA showed increased
swelling with time up to a maximum of 18% after 72 hours in culture. Samples treated with
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I mM APMA + 40 nM TIMP or 1 mM APMA + 40 nM MC 1 both showed little increase in
swelling ratio after three days in culture, and the difference between these treatments and
controls was not statistically significant. Higher doses (400 nM and 40 PM) of TIMP and
MC1 were also tested, and plugs which received these treatments demonstrated swelling
behavior similar to that of control plugs after three days in culture (data not shown).
4.4.3 Biomechanical and Electromechanical Evaluation
Treatment with I mM APMA resulted in dramatic decreases in streaming potential (Fig
4.5A) and electrokinetic coupling coefficient (Fig 4.5B) in cartilage disks after 1 day in
culture [97]. Measured values of streaming potential ranged from 33.5 IuV/% at 0.01 Hz
to 133.8 [uV/% at 1 Hz and the electrokinetic coupling coefficient was calculated to be
1.92 x 10- 9 V/Pa for control plugs at the start of the experiment and did not differ sig-
nificantly over 3 days in culture. Although values of streaming potential did vary with
frequency of testing as expected [40], the relative changes in streaming potential with time
were independent of frequency (Fig 4.5).
Treatment with 1 mM APMA also resulted in dramatic decreases in dynamic stiff-
ness (Fig 4.6A) and equilibrium confined compression modulus (Fig 6B) in cartilage disks
after 3 days in culture. Measured values of dynamic stiffness ranged from 3.88 MPa at
0.01 Hz to 10. 13 MPa at 1 Hz and equilibrium modulus was 1.47 MPa for control plugs at
the start of the experiment and did not differ significantly over 3 days in culture. Similar
to the streaming potential, the relative decreases in dynamic stiffness were independent of
frequency.
The addition of 4 /,M TIMP to the culture media affected changes in the physical
properties of cartilage disks treated with APMA (Fig 4.7). In particular, the electromechan-
ical properties, streaming potential and electrokinetic coupling coefficient of disks treated
with 1 mM APMA were <20% and -50% respectively of the values of disks which re-
ceived 1 mM APMA with 4 fM TIMP after three days in culture. The purely mechanical
properties of APMA-treated disks, equilibrium modulus and dynamic stiffness, were -50%
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and ,60% respectively, of disks which were cultured with both 1 mM APMA and 4 ILM
TIMP for three days.
4.5 Discussion
4.5.1 Biochemical Analyses
The specificity of matrix degradation is demonstrated in Figure 4.1. Treatment with 1 mM
APMA resulted in significant GAG loss which was inhibited completely by simultaneous
treatment with the MMP inhibitor, TIMP. Furthermore, the use of non-MMP proteinase
inhibitors during APMA treatment did not significantly alter GAG loss, implying that
MMP are responsible for the PG degradation seen in these experiments. This is of special
concern, given that radiolabel incorporation data showed that the tissue did not synthesize
[35S]sulfate or [3H]proline labeled molecules, suggesting that the chondrocytes were non-
viable. In such circumstances, cell death might result in release of a variety of proteinases
capable of degrading the tissue matrix. However, this does not appear to be the case in this
system, where MMPs specifically appear to be the cause of GAG loss. In addition, the lack
of biosynthetic activity by the chondrocytes indicates that MMPs are not being produced
during the course of the culture, and that the degradation which occurs results from activity
of enzymes which are present in the tissue at the start of culture.
The amount of PG degradation which resulted from APMA treatment showed some
variation between experiments (Figs 4.1 and 4.2). This is not unexpected, since the observed
GAG loss will be a function of the amount of endogenous MMP and MMP inhibitors
present in the tissue, which is likely to vary greatly between individual animals. In both
cases presented here, the activation of the MMPs native to the tissue resulted in significant
loss of PG, up to 80% after 3 days.
This degradation by endogenous MMPs was completely inhibited by the presence
of 4 iM TIMP in the culture media (Fig 4.2A). This indicates that the TIMP in the culture
media was able to penetrate the cartilage matrix. This is in contrast with previous studies
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Figure 4.1: Normalized GAG loss from cartilage disks incubated in DMEM alone or DMEM
with 1 mM APMA, 1 mM APMA + 4 jM TIMP, or 1 mM APMA + a proteinase inhibitor
cocktail without a metalloproteinase inhibitor. Data are mean + SD (n=4), reported as
GAG remaining in the tissue normalized to total GAG (tissue + media GAG) at each time
point.
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Figure 4.2: A: Normalized GAG loss from cartilage disks incubated in DMEM alone or
DMEM with 1 mM APMA + graded levels of tissue inhibitor of metalloproteinases (TIMP)
ranging from 40 nM to 4 p/M. B: Normalized GAG loss from cartilage disks incubated in
DMEM alone or DMEM with 1 mM APMA + graded levels of a synthetic metalloproteinase
inhibitor (MC1) ranging from 40 nM to 4 tM. Data are mean - SD (n=4).
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Figure 4.3: Type II collagen denaturation as determined by ELISA for a/(II)-CB11B pep-
tide in cartilage disks cultured in DMEM alone, DMEM with 1 mM APMA, or DMEM
with 100 pg/ml recombinant human stromelysin for 72 hours. The amount of denatured
type II collagen was normalized to total amount of type II collagen to give a percentage
denaturation. Data are mean ± SD (n=3).
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Figure 4.4: Swelling ratio (wet weight in 0.01 M NaCI normalized to wet weight in DMEM)
of cartilage disks cultured in DMEM alone, DMEM with 1 mM APMA, DMEM with 1 mM
APMA + 40 nM TIMP, or DMEM with 1 mM APMA + 40 nM MC 1. Data are mean ± SD
(n=4).
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Figure 4.5: A: Streaming potential of cartilage disks of cultured in DMEM alone or DMEM
with 1 mM APMA as a function of time in culture. Data are mean ± SD (n = 4); mean values
are normalized at each frequency to the value at t = 0. B: Electrokinetic coupling coefficient
of disks of cultured in DMEM alone or DMEM with 1 mM APMA as a function of time in
culture. Data are mean + SD (n = 4); mean values are normalized to the value at t = 0.
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Figure 4.6: A: Dynamic stiffness of cartilage disks of cultured in DMEM alone or DMEM
with 1 mM APMA as a function of time in culture. Data are mean ± SD (n = 4); mean
values are normalized at each frequency to the value at t = 0. B: Equilibrium modulus of
disks of cultured in DMEM alone or DMEM with 1 mM APMA as a function of time in
culture. Data are mean ± SD (n = 4); mean values are normalized to the value at t = 0.
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Figure 4.7: Streaming potential at 1 Hz, electrokinetic coupling coefficient, dynamic stiff-
ness at 1 Hz, and equilibrium modulus of cartilage disks cultured in the presence of 1 mM
APMA or 1 mM APMA + 4 ,M TIMP for 72 hours. Data are mean + SD (n = 4); mean val-
ues for each property were normalized to the mean value of disks which received treatment
with 1 mM APMA + 4 pM TIMP.
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in which lower doses of TIMP (-50 nM) were unable to inhibit PG loss induced by IL-la
treatment, presumably due to transport restrictions [1]. The fact that addition of TIMP to
the culture media was not as effective at inhibiting degradation as MC 1 is interesting, in that
in studies on digestion of peptide substrates in solution TIMP is a far more potent inhibitor
of MMP than MC1 (ki of TIMP against stromelysin: <1 nM [70] vs. ki of MC1 against
stromelysin: -300 nM [22]). In the present study, however, there is the added complication
that any inhibitor present in the culture media must penetrate into the tissue to inhibit the
endogenous MMP activated by APMA. Since TIMP is quite large (-25 kDa), it is likely
that its transport through the cartilage matrix is hindered. Based on the partitioning of
similarly sized proteins into cartilage [79], the amount of TIMP which penetrates into the
tissue may be as little as 1% of that which is added to the culture media; thus, a 4 AM culture
media concentration could result in an intratissue concentration as small as -40 nM. This
is in contrast to MC1, which is quite small (-500 Da) and consequently not hindered in its
movement into the tissue. Thus, characteristics of transport through the cartilage matrix
seem to have an important impact on the overall efficacy of treatment with MMP inhibitors.
The results of the ELISA for presence of the cal(II)-CB11B peptide sequence
revealed that APMA treatment caused significant damage to the collagen network as well
as damage to PG network. The appearance of this epitope indicates that type II collagen is
in an unwound or denatured state. The presence of APMA in the culture media for 3 days
resulted in denaturing of -7% of the type II collagen in cartilage explants, compared to
,-,2% in control tissue. Hollander et al showed that exposure of type II collagen to either
bacterial or recombinant human collagenase resulted in collagen denaturation and exposure
of the a 1(II)-CB 11B epitope. It seems likely that the type II collagen denaturation seen here
is the result of collagenase activity, given that exposure of explants to active stromelysin
did not increase the presence of the ac(II)-CB11B epitope. This is inherently interesting
in that active stromelysin has been shown to activate procollagenase [119,120] in solution,
yet there is no evidence of this occurring in these cartilage explants (Fig 4.3).
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4.5.2 Swelling Studies
The damage to matrix collagens in consistent with the increased swelling response of carti-
lage disks treated with APMA (Fig 4.4). As described by Maroudas [78], the swelling state
of cartilage is determined by a balance between the osmotic pressure of the proteoglycans
which tends to swell the tissue and the restraining tensile forces of the collagen network,
which tend to limit tissue swelling. If the collagen network is compromised, as in OA
[78], it is less able to counteract the osmotic swelling forces, and the tissue swells. The
unwinding of type II collagen fibrils caused by APMA treatment weakens the cartilage ma-
trix, making it less able to counteract osmotic swelling pressure. Previously it was shown
that stromelysin treatment resulted in an increased swelling response, presumably due to
damage to type IX collagen [8]. Given that APMA is likely activating prostromelysin as
well as procollagenase, it is possible that type IX collagen has also been degraded, further
contributing to the swelling response.
Addition ,of 40 nM TIMP or MC 1 to the culture with APMA resulted in a swelling
response which was indistinguishable from controls. Presumably, this indicates that the
inhibitors are preventing the damage to the collagen network which causes the swelling re-
sponse. It is interesting that at 40 nM, TIMP and MC 1I did not inhibit GAG loss completely,
but appeared to prevent collagen damage. This is consistent with studies of IL- 1 a degrada-
tion of cartilage, which have shown that collagen damage, as indicated by hydroxyproline
release, could be completely inhibited by doses TIMP or synthetic inhibitors which did
not completely prevent PG degradation [1,29]. It is possible that this is due to restricted
transport of enzymes through the cartilage matrix. Degradation can only take place when
collagenases have access to tissue collagens. With the PG network intact, collagenase
transport is restricted. Thus, it may be necessary for the PG to be cleared out before the
collagen network. is significantly damaged.
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4.5.3 Biomechanical and Electromechanical Evaluation
The large decreases in electromechanical properties of the tissue are consistent with severe
degradation of matrix PG (Fig 4.5). As in previous studies, the magnitude and kinetics of
streaming potential are similar to changes in tissue GAG content [8,41], since loss of GAG
reduces tissue fixed charge density, thus lowering the charge separation which occurs due
to fluid flow. The changes in streaming potential with time were similar at all frequencies
tested. This is in contrast to previous studies of stromelysin degradation of cartilage [8],
where the decrease in streaming potential was highly frequency dependent. In such studies,
the degradation of cartilage explants was initially localized at the tissue surface, due to the
restriction of transport of the large enzyme into the tissue. APMA (-500 Da), however,
is much smaller than stromelysin (.50 kDa) and can activate MMP throughout the tissue,
causing a more spatially uniform degradation of this tissue. As a result, at any time
during the course of the experiment the fixed charge density of degraded samples is similar
through all sections of the tissue and relative changes in streaming potential are similar at
all frequencies.
The electrokinetic coupling coefficient is a material property which reflects the
amount of potential developed due a given stress. Thus, while the streaming potential
decreases (as described above), the stress developed in the tissue, reflected in the dynamic
stiffness (Fig 4.6A), also decreases. As a result, there is a net decrease in the coupling
coefficient ('50%) but it is not as dramatic as the changes in streaming potential.
Changes in dynamic stiffness and equilibrium modulus of cartilage disks are due
to degradation of both PG and collagen matrix constituents (Fig 4.6). Electrostatic inter-
actions between charge groups on GAG chains serve to stiffen cartilage in compression.
Previous studies have shown that neutralization or shielding of proteoglycan fixed charge
groups (by pH or ionic strength alteration) or removal of charge bearing GAG chains by
enzymatic treatment could decrease the modulus or dynamic stiffness of cartilage disks by
approximately 50% [28,41,42]. Given that the dynamic stiffness and equilibrium modu-
lus decrease to -20% of their initial value and that swelling studies and ELISA revealed
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damage to the collagen network, it seems likely that collagen damage contributed to the
changes in mechanical properties as well.
As detailed previously, addition of 4/ M TIMP to the culture media effectively
inhibited the degradation of cartilage matrix components induced by APMA, and this is
reflected in the study of physical properties as well (Fig 4.7). After three days in culture,
cartilage disks cultured with APMA but not TIMP had values for coupling coefficient,
dynamic stiffness, and equilibrium modulus which were -50% and streaming potential
which were -20% of those which received treatment with TIMP as well as APMA. This
is consistent with previous studies [8,28,41,42,65] which relate enzymatic cartilage matrix
with changes in physical properties and indicates that it is possible to prevent these changes
by inhibiting the enzymatic degradation.
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Chapter V
Inhibition of Cartilage Degradation and Changes in
Physical Properties Induced by IL-10, Retinoic Acid, and
APMA.
5.1 Abstract
Bovine cartilage explants were treated with 1 mM 4-aminophenylmercuric acetate (APMA),
100 ng/ml recombinant human interleukin- 1/ (IL-1 3) or 1 pM all-trans retinoic acid (RA)
and changes in biochemical, biomechanical, and physicochemical properties were assessed.
Additionally, samples cultured with APMA, IL-10/, or RA were treated with 4 iM recom-
binant human tissue inhibitor of metalloproteinases- 1 (TIMP) to inhibit this degradation.
C-artilage explants treated with APMA lost 60% of tissue GAG after 3 days in culture, while
treatment with IL-1/3 or RA each resulted in >90% GAG loss after 8 days in culture. IL-10
induced a significant increase in swelling ratio (wet weight in 0.01 M NaC1 normalized to
wet weight in DMEM) after 8 days in culture, while swelling behavior of RA treated tissue
was indistinguishable from controls at all time points. Addition of TIMP to the culture me-
dia inhibited loss of tissue GAG by >95%, 40%, and 35% respectively from samples treated
with APMA, IL- 1/3, or RA. Measurements of equilibrium modulus and streaming potential
of tissue treated with APMA plus TIMP were significantly higher than APMA samples
which were not exposed to TIMP. Streaming potential and equilibrium modulus of IL-10
treated samples both decreased to 10% of their initial values after 8 days in culture, while
those treated with IL-1/3 and TIMP showed decreased by only 50% and 10% respectively.
Measurement of dynamic streaming potential showed that changes due to treatment with
IL-10 alone were strongly dependent in compression frequency, with dramatic changes
seen at high frequency prior to changes in mechanical properties, and little initial change
seen at low frequency. Streaming potential and equilibrium modulus of RA treated samples
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both decreased to 10% of their initial values after 8 days in culture, while those treated with
RA and TIMP showed decreased by only 60% and 10% respectively.
5.2 Introduction
Both interleukin-1 and retinoic acid have been commonly used to induce cell-mediated
degradation of cartilage explants. Interleukin-1 (IL-1) is an 18 kD cytokine produced by
several cell types including endothelial cell, synoviocytes and chondrocytes [114]. Although
typically associated with inflammatory diseases such as rheumatoid arthritis [24,82], both
the a and 3 forms of IL-1 have been shown to be relevant to degradation in osteoarthritis as
well [94,101]. IL-1 interacts with chondrocytes by means of a receptor on the cell surface
[21]. Stimulation of cartilage explants with IL-1 has been shown to result in widespread
matrix degradation, including loss of tissue PGs [4,16,6 1] and collagens [ 16]. IL- 1 treatment
directly influences cell metabolism, decreasing synthesis of PGs [4,16,85,121] and collagens
[46,47,122] while decreasing chondrocyte proliferation [43]. Additionally, IL-1 induces
production and mRNA expression of MMPs in chondrocytes [63,64], while modulating
production of TIMP [ 114]. Although tissue treated with IL-1 contains an excess of MMPs,
the PG degradation products which result are not those typically associated with MMP
cleavage [108]. These fragments, however, are similar to those found in human OA patients
[111]. Despite this apparent discrepancy, MMP inhibitors have been shown to be effective
at inhibiting cartilage matrix degradation induced by IL-1 [16,87,113].
The vitamin A derivative all-trans retinoic acid (RA) has also been shown to induce
widespread matrix degradation in cartilage explants. [16,86]. RA stimulation involves
interaction with a nuclear receptor, directly altering DNA transcription [93]. On the tissue
levels, RA treatment results in loss of tissue PGs and collagens [16,17,86] decreased
synthesis of PG [86] and collagens [26,136] by chondrocytes. RA has also been shown
to induce expression and production of MMPs [16], although degradation products from
such systems are not those typically associated with MMP activity (JD Sandy, unpublished
results). This matrix degradation inhibited in the presence of MMP inhibitors, but not in
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the presence of inhibitors of cathepsin B [16].
While the degradative action of IL-1 and RA have been well documented, the
effects of this degradation on the physical properties of cartilage explants have not been
characterized. In addition, the use of synthetic MMP inhibitors to prevent degradation
induced by IL-1 or RA has been demonstrated [16,87,113], while the inhibition of PG loss
by TIMP in these systems has not been documented. The cartilage degradation induced
by the presence of APMA provides a valuable comparison for these systems, given that
the degradation in the APMA system is known to be caused by the action of MMPs [10]
and chondrocytes are known to be metabolically inactive. Therefore, the objectives of
this study were (1) to quantify the effects of IL-10 and RA treatment on the physical
properties and proteoglycan loss of cartilage explants, (2) to characterize the modulation of
this degradation by tissue inhibitor of metalloproteinases (TIMP) and (3) to compare these
results to the effects of activation of endogenous MMPs by APMA and inhibition of this
degradation by TIMP.
5.3 Methods
5.3.1 In Vitro Culture
Saddle sections of 1-2 week old calves were obtained from a local abbatoir (A. Arena,
Hopkington, MA) within four hours of slaughter. The femoropatellar groove was isolated
and 3 mm diameter x 1 mm thick cartilage disks were harvested using a dermal punch
(Miltex Instruments, Lake Success, NY) and a sledge microtome (Model 860, American
Optical, Buffalo, NY) as described previously [105]. Groups of 4 plugs were maintained
in culture at 37 oC in a 5% CO 2 atmosphere for up to 8 days in 1 ml DMEM containing one
of the following treatments: (a) 1 mM 4-aminophenylmercuric acetate (APMA) (Sigma,
St. Louis, MO), (b) 100 ng/ml recombinant human IL-l10, or (c) 1 pM retinoic acid (RA)
(Sigma) in 0.1% dimethylsulfoxide (Sigma) in the presence or absence of 4 IM recombinant
human TIMP-1. Media for IL- 10 or RA experiments also contained 0.1% bovine serum
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albumin (Sigma) and was changed every two days.
The protocol for swelling studies was motivated by the technique used by Maroudas
[78] to compare the swelling of normal and cartilage. Upon removal from culture disks were
removed from culture medium and patted briefly with a paper towel to remove surface water,
and wet weights were measured (AE 163 Balance, Mettler Instrument Corp, Hightstown,
NJ). Disks were then twice reequilibrated in 1 ml of hypotonic saline solution (0.01 M NaCI
at pH 7.0) for 1 hour at room temperature. Surface water was again removed and wet weights
were measured. Following wet weight measurements, disks were lyophilized, and dry
weights were recorded. Previously, it has been shown that this method is sensitive to damage
to the cartilage matrix collagens, but is not sensitive to changes in tissue proteoglycan
content [8]. After swelling measurements, lyophilized samples were digested with 1 ml of
125 pg/ml papain digestion solution (Sigma) and assayed for sulfated GAG by reaction with
2 ml of dimethylmethylene blue dye solution in polystyrene cuvets (VWR, Boston, MA)
and spectrophotometry (Model A3B, Perkin Elmer, Norwalk, CT) [34] using whale/shark
chondroitin sulfate (Sigma) as the standard.
5.3.2 Physical Properties
Cartilage disks were placed in an electrically insulating poly(methylmethacrylate) cylindri-
cal confining chamber, similar to that used by Frank et al [41]. The chamber was mounted in
a servo-controlled Dynastat mechanical spectrometer (IMASS, Hingham, MA) which was
interfaced to a computer and frequency generator (Model 5100, Rockland Systems, West
Nyack, NY). Samples were equilibrated in 0.15 M phosphate buffered saline (PBS)(Gibco)
at pH 7.4 containing 100 U/ml penicillin G and 100 p/g/ml streptomycin at room tempera-
ture. Disks were subjected to confined compression between a porous polyethylene platen
and a 6.35 mm Ag/AgCl pellet electrode (Annex Research, Costa Mesa, CA) mounted at
the base of the chamber. An identical electrode was mounted in the surrounding PBS bath.
Disks were first compressed by sequential increments of 0.5-1.5% strain, up to a
maximum of 20% total strain. After stress relaxation, the equilibrium stress correspond-
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ing to each increment of static strain was detected with the load cell of the Dynastat and
recorded on the computer. The resultant equilibrium stress was plotted against applied
strain and the slope of the best fit linear regression curve gave the equilibrium confined
compression modulus. At a given static offset strain, sinusoidal strains of <1% amplitude
were superimposed on the static strain at frequencies ranging from 0.01 Hz to 1 Hz. The
resultant oscillatory load was detected by the load cell and the oscillatory streaming po-
tential was detected by the chamber electrodes which were connected to a high-impedance
Universal Amplifier, Model 11-4113-02 (Gould, Inc., Cleveland, OH). Load and streaming
potential were simultaneously recorded by the computer. The amplitude of the dynamic
load was normalized to disk area and to the amplitude of the applied strain to give dynamic
stiffness, while the amplitude of the streaming potential was normalized to the amplitude
of the applied strain [39,40]. Equilibrium modulus and dynamic stiffness data were used
in combination with the method of Frank and Grodzinsky [40] to calculate the effective
hydraulic permeability of the tissue specimen. In all tests the amplitude of the applied
strain was chosen to be small enough to elicit a linear mechanical response from the sample
[39,40] (i. e. the total harmonic distortion in the measured load was <10%). The porous
platen remained in contact with the sample at all times during the testing cycle.
5.4 Results
5.4.1 In Vitro Culture
Incubation of cartilage explants in the presence of 1 mM APMA resulted in ,,75% loss of
tissue GAG after three days in culture, which was completely inhibited by the presence of
4 jiM TIMP in culture media (Fig 5.1). Treatment with 100 ng/ml IL-1fl resulted in >90%
loss of tissue GAG after 6 days in culture, compared to ,60% loss from samples exposed to
4 MM TIMP and 100 ng/ml IL-lfl, and - 15% loss in controls samples incubated in DMEM
alone (Fig 5.2A). Additionally, samples treated with 100 ng/ml IL-1 # had a swelling ratio
of 1.07 after 8 days in culture, compared to 1.03 for samples treated with 1 MM RA and
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Figure 5.1: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 mM APMA, DMEM with 1 mM APMA plus 4 /tM TIMP. Data are plotted as mean
± SD (n=4).
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Figure 5.2: A: Normalized GAG loss from cartilage disks incubated in DMEM alone,
DMEM with 100 ng/ml IL-1/3, DMEM with 100 ng/ml IL- 10 plus 4 jLM TIMP B: Swelling
ratio (wet weight in 0.01 M NaCI normalized to wet weight in DMEM) of cartilage disks
incubated in DMEM alone, DMEM with 100 ng/ml IL-13, or DMEM with 1 jIM retinoic
acid. Data are plotted as mean ± SD (n=4).
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Figure 5.3: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 j/M RA, DMEM with 1 IM RA plus 4 pM TIMP. Data are plotted as mean ± SD
(n=4).
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Figure 5.4: A: Time course of streaming potential for cartilage disks incubated in DMEM
with 1 mM APMA or DMEM with 1 mM APMA plus 4 ftM TIMP. Data are normalized
to values of disks treated with APMA plus TIMP at each time point. B: Time course of
equilibrium modulus for cartilage disks incubated in DMEM with 1 mM APMA or DMEM
with 1 mM APMA plus 4 IM TIMP. Data are normalized to values of disks treated with
APMA plus TIMP at each time point. Data are plotted as mean ± SD (n=4).
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Figure 5.5: A: Time course of streaming potential for cartilage disks incubated in DMEM
with 100 ng/ml IL-131, DMEM with 100 ng/ml IL-10 4 pM TIMP. Data for each treatment
group are normalized to values of disks on day 0. B: Time course of equilibrium modulus
for cartilage disks incubated in DMEM with 100ng/ml IL-13, DMEM with 100ng/ml
IL- 10 4 IM TIMP. Data for each treatment group are normalized to values of disks on day
0. Data are plotted as mean ± SD (n=4).
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Figure 5.6: A: Time course of streaming potential for cartilage disks incubated in DMEM
with 1 /IM RA, DMEM with 1 /M RA plus 4 IM TIMP. Data for each treatment group are
normalized to values of disks on day 0. B: Time course of equilibrium modulus for cartilage
disks incubated in DMEM with 1 /M RA, DMEM with 1 IM RA plus 4 /LM TIMP. Data
for each treatment group are normalized to values of disks on day 0. Data are plotted as
mean ± SD (n=4). Section 5.4
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1.02 for controls (Fig 5.2.B). RA treatment resulted in >90% loss in tissue GAG after 8
days in culture, compared to , 15% for control samples, while tissue treated with 1 /M RA
plus 4 /zM TIMP lost '70% of tissue GAG over this time period (Fig 5.3).
5.4.2 Physical Properties
The streaming potential and equilibrium modulus of tissue treated with 1 mM APMA or
1 mM APMA + 4 ILM TIMP was normalized to the values of the samples treated with
APMA plus TIMP at each time point (Fig 5.4). Values for streaming potential ranged from
65.1 + 13.1 /tV/% at 0.01 Hz to 392 + 37.1 ,/V/% at 1 Hz, and the equilibrium modulus was
measured to be 1.19 + 0.22 MPa at the start of the culture. The streaming potential at 1
and 0.01 Hz and the equilibrium modulus of APMA treated samples decreased to <10%
and -,60%, respectively, of those of samples treated with APMA plus TIMP after 3 days in
culture, and both differed significantly from these samples after 1 day in culture.
Treatment with IL-1i resulted in decreases in streaming potential and modulus
to • 15% of initial values after 8 days in culture (Fig 5.5). Streaming potential at 1 Hz
decreased by -50% after only 2 days in treatment, while streaming potential at 0.01 Hz
decreased more slowly, showing only a 10% decrease after 2 days in culture. Addition of
TIMP to the culture media inhibited the degradation of proteoglycans and the reduction in
physical properties. Loss of streaming potential at 1 and 0.01 Hz was inhibited by 40% and
loss in modulus by 100% compared to controls after 8 days in culture. Similarly, treatment
with RA resulted in a decrease in streaming potential at all frequencies and in equilibrium
modulus to <10% and -30% of initial values after 8 days of treatment (Fig 5.6). With
TIMP added to the RA culture media, the losses in streaming potential at all frequencies
and modulus were inhibited by 40% and 90% respectively, compared to controls.
5.5 Discussion
In all experiments, the addition of TIMP to the culture media significantly inhibited degra-
dation of cartilage proteoglycans and changes in physical properties. Inhibition of GAG loss
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induced by exposure to APMA is consistent with previous studies which have demonstrated
that matrix degradation is due to the activation of native latent MMPs [9]. N-terminal analy-
sis has shown that proteoglycan fragments lost to media after incubation with APMA are
predominantly due to cleavage at the VDIPEN-FFGVG site associated with MMP activity
[109]. Given that MMPs appear to be the only cause of degradation in this system, the
inhibition of MMPs by TIMP prevents matrix degradation (Fig 5.1) and prevents changes
in tissue physical properties (Fig 5.4).
The time course of loss of GAG from samples treated with IL-1 or RA was similar
to previous studies [16,87,113]. IL-10 treatment resulted in negligible GAG loss after two
days in culture, followed by loss of >90% of tissue GAG in the four days which followed.
This two day lag in loss of GAG may be a result of the time necessary for IL-10 to diffuse
through the cartilage matrix and affect chondrocyte metabolism. In contrast, response to
RA treatment was more rapid, with >60% loss of GAG after only two days in culture,
consistent with the fact that RA is much smaller than IL- 1 and would likely diffuse more
easily through the cartilage matrix.
In addition, a swelling response was induced by treatment with IL-1 #, but not RA
(Fig 5.2B). This may indicate that the mechanisms for degradation of matrix collagens
initiated by IL- 10 and RA differ significantly. This swelling data is particularly interesting
in that RA appeared to degrade matrix proteoglycans more quickly than IL- 10, but did not
appear to have as much of an effect on matrix collagens as IL-10.
The addition of 4 [tM TIMP to the culture media significantly inhibited GAG loss
induced by exposure to IL-10 (Fig 5.2) or RA (Fig 5.3). The inhibition in the IL-10
and RA systems reveals that portions of the associated degradative pathways were at least
partially blocked, suggesting that MMPs play a role in the mechanisms of degradation.
Given that both IL-10 and RA are known to upregulate MMP production [15,64] as well
as downregulate production of native MMP inhibitors [114], it is possible that the amount
of TIMP which was sufficient to inhibit the endogenous MMPs activated by APMA is
not sufficient to inhibit the additional MMPs produced in the tissue due to stimulation by
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100 ng/ml IL-10/ or 1 piM RA. It is also possible that the TIMP added to the culture media
has inhibited all MMPs in the system and that the remaining degradation has occurred
through pathways which are independent of MMPs.
On a more basic level, these results also indicate that TIMP is indeed able to penetrate
the dense cartilage matrix when added to the culture media. This is in contrast to previous
studies in which TIMP treatment did not alter GAG loss from tissue treated with IL-la [1],
perhaps due to insufficient intratissue TIMP concentration. Based on the partitioning of
similarly sized proteins into cartilage [79], the amount of TIMP which penetrates into the
tissue may be as little as 1% of that which is added to the culture media; thus, a 4 jIM culture
media concentration could result in an intratissue concentration as small as -40 nM. It is
therefore necessary to have a concentration of TIMP in the culture media which is far in
excess of MMP levels expected inside the tissue, since only a small fraction will penetrate
into the tissue.
The more rapid loss of high frequency streaming potential at early time points in IL-
10 treated samples is similar to that seen for samples treated with activated stromelysin [8],
and suggests that at early times, degradation is localized to regions near the tissue surface.
It is also of interest that the equilibrium modulus did not decrease as much or as quickly as
the streaming potential in either the IL-1/p or RA systems, and was more easily preserved
by the addition of TIMP to the culture media. This is consistent with previous observations
that streaming potential is more sensitive to loss of proteoglycans than measurements such
as equilibrium modulus [39], which reflect the contributions of other matrix components
such as collagen, which may be degraded more slowly than proteoglycans [1].
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Chapter VI
Summary and Future Work
6.1 Summary
6.1.1 Stromelysin In Vitro Model
On the most basic level, in vitro studies revealed that activated stromelysin is capable of
degrading several types of cartilage matrix molecules in intact tissue. Additionally, levels
of stromelysin which are thought to be physiologic [74], caused matrix degradation on a
short time scale, with -40% loss of glycosaminoglycan (GAG) content after 72 hours at
a concentration of 200 nM. N-terminal sequencing of degradation products confirmed that
SLN was responsible for proteoglycan cleavage. Further analysis showed the presence of
elevated levels of type IX collagen fragments within treated explants and in the incubation
media. Histological examination demonstrated that proteoglycan loss proceeded inward
from the exposed tissue surfaces, with a marked boundary between degraded and undegraded
tissue. Physicochemical studies revealed that stromelysin treatment resulted in tissue
swelling, while enzymes known to remove proteoglycans, but not affect matrix collagens,
did not. Stromelysin treated tissue exhibited marked decreases in equilibrium modulus and
dynamic stiffness and a substantial increase in hydraulic permeability by 72 hours, with
similar kinetics to the loss of GAG. The significant decreases in equilibrium modulus and
dynamic stiffness, together with swelling and the loss of type IX collagen fragments suggest
that the structural integrity of the collagen network had been compromised. Measurement
of dynamic streaming potential showed that changes due to stromelysin treatment were
strongly dependent in compression frequency, with dramatic changes seen at high frequency
prior to changes in mechanical properties, and little initial change seen at low frequency.
Streaming potential, an electrokinetic phenomenon, was therefore a more sensitive indicator
of initial, focal loss of GAG from the tissue due to stromelysin treatment than purely
mechanical measurements such as dynamic stiffness.
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6.1.2 Stromelysin In Vivo Model
Results from experiments involving intraarticular injection of stromelysin into rabbit stifle
joints are consistent with data from studies of stromelysin degradation of cartilage explants
in vitro. After one hour of exposure to stromelysin, significant amount of proteoglycan
was lost to synovial fluid. Histology indicated that during this short time exposure, loss of
PGs from joint cartilage occurred in a small region near the tissue surface. Toluidine Blue
staining for GAG and immunoperoxidase staining of VDIPEN antibodies showed that the
loss of GAG in these experiments was due to stromelysin activity. Assays for PG content
of full thickness disks removed from the femoropatellar groove showed that tissue samples
from treated and untreated joints had similar amounts of GAG, indicating that depth of
penetration of matrix degradation was relatively small. With the bulk of the matrix intact,
mechanical measurements of dynamic stiffness and equilibrium modulus were similar in
samples of cartilage from treated and control joints. High frequency streaming potential
measurements of cartilage disks from treated joints were significantly less than those from
control joints, demonstrating the sensitivity of such measurements to focal changes in
GAG content. Systemic administration of a MMP inhibitor (MC1) prior in intraarticular
injection of stromelysin significantly modulated all indicators of cartilage degradation. Loss
of PG fragments were significantly inhibited, appearance of VDIPEN epitope and loss of
Toluidine Blue staining for GAG was significantly decreased, and all physical property
measurements, including high frequency streaming potential, were similar between treated
and control joints for animals which received an intravenous dose of MC . Due to transport
restrictions, it is likely that stromelysin did not penetrate the cartilage matrix and that
the majority of the enzyme was present in the synovial fluid. In animals which received
intravenous injection of MCi, it is likely that the synovial fluid also contained high levels
of MC 1, which inhibited stromelysin before it could degrade the joint cartilage.
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6.1.3 Activation of Metalloproteinases by APMA
Observations from APMA experiments indicated that under normal physiologic conditions,
cartilage contains significant amount of latent MMPs, which are capable of causing wide-
spread matrix degradation upon activation. Treatment with APMA resulted in as much as
80% loss in tissue proteoglycan content and a > 3-fold increase in the presence of denatured
type II collagen as determined by the presence of CB 11B peptide after 3 days in culture.
This underscores the role of chondrocytes in maintaining matrix homeostasis. With such
a high basal level of tissue proteases, activation mechanisms must be tightly controlled to
avoid uncontrolled enzyme activity and unwanted matrix destruction. Assessment of phys-
ical behavior indicated that matrix degradation had a profound effect on tissue functional
properties. Physicochemical studies revealed that APMA treatment resulted in a significant
increase in tissue swelling response, consistent with damage to the collagen network.
Activation of MMPs by APMA also resulted in >80% decrease in equilibrium
modulus, dynamic stiffness, and streaming potential and >50% decrease in electrokinetic
coupling coefficient. The addition of 4 tiM, 400 nM and 40 nM TIMP inhibited PG loss by
95%, 50%, and 20%, respectively and all doses effectively inhibited swelling response. The
addition of 4 ILM and 400 nM MC1 inhibited PG loss by 95% while 40 nM MC1 inhibited
PG loss by 60%, and all doses effectively inhibited swelling response. Cartilage disks
treated with 4 pM TIMP and 1 mM APMA had significantly greater streaming potential,
electrokinetic coupling coefficient, dynamic stiffness and equilibrium modulus than disks
treated with APMA.
6.1.4 Degradation Induced by IL-1f and Retinoic Acid
Similar to several previous studies [1,87,113], addition of IL-10 or RA to culture media
resulted in >90% loss of proteoglycans after 6 days in culture. Additionally, tissue samples
treated with IL-1/ showed a significant increase in tissue swelling response after 8 days in
culture, while those treated with RA showed no changes in swelling behavior. Cartilage
explants treated with APMA showed significant loss of GAG after 3 days in culture, similar
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to previous studies (Chapter IV).
Cartilage disks cultured in the presence of IL-10 showed a significant decreases
in equilibrium modulus and streaming potential after 8 days in culture. Loss of stream-
ing potential showed a marked frequency dependence, with high frequency measurements
decreasing more quickly than low frequency measurements. This is consistent with degra-
dation which is localized to regions near the sample surface, due to the restricted transport
of the large cytokine (18 kDa) through the cartilage matrix. The pattern of degradation and
changes in electromechanical behavior to those induced by treatment with active stromelysin
(Chapter II). Degradation induced by treatment with RA resulted in significant decreases
in equilibrium modulus and streaming potential measurements. In contrast to IL-10 ex-
periments, the changes in streaming potential were independent of frequency. This is
presumably due to a more uniform pattern of matrix degradation, since RA is relatively
small (400 Da) and its transport through the cartilage matrix should not be hindered by size
considerations. This is similar to degradation induced by APMA activation of endogeonous
MMPs.
Addition of TIMP to IL-10, RA, or APMA cultures significantly inhibited matrix
degradation. Loss of matrix PG was inhibited by 40%, 35%, or 95% in IL-1,3, RA, or
APMA systems, respectively. Inhibition of matrix degradation also modulated changes
in physical properties due to IL-1#, RA, or APMA treatment. Equilibrium modulus and
streaming potential of samples treated with APMA and TIMP were significantly higher
than those treated with APMA alone. Decreases in streaming potential and modulus related
to IL- 1 or RA treatment were also significantly inhibited by addition of TIMP to culture
media. Previous studies were unable to verify that TIMP could inhibit IL-1 f-induced PG
degradation [1], presumably due to its inability to penetrate into the cartilage matrix. These
results clearly show that TIMP was able to penetrate into cartilage and prevent PG and
concomitant changes in physical properties due to activation or production of endogenous
MMPs.
Section 6.1
-117-
6.2 Future Work
6.2.1 Stromelysin In Vitro Model
Previous studies suggest that the pH for maximal stromelysin activity is in the range of
5.0-5.5 [131], much more acidic than the neutral conditions once presumed to be optimal.
The idea that more acidic conditions could increase stromelysin activity and possibly affect
the manner in which it cleaves the aggrecan core protein warrants further investigation.
Given that the internal pH of cartilage is likely to be less than that of the culture media due
to Donnan partitioning, the activity of stromelysin as a function of pH is an area of concern.
Experiments involving culture of explants at lower pH could at least address the question of
substrate specificity and could also give insight as to mechanisms of cartilage degradation.
6.2.2 IL-10 and Retinoic Acid Stimulation
The results of Chapter V motivate additional investigation of inhibition of degradation of
IL-10 and RA treated explants. While studies have demonstrated that such treatments
result in production of "aggrecanase" generated fragments [108] and that this degradation
can be inhibited by MMP inhibitors [16,87,113], it is unclear which enzymatic processes
are being inhibited. The use of antibodies to cleavage fragments which are present with
and without inhibitor treatment would give insight into which proteinases are relevant to
particular degradative processes.
Additionally, the difference in swelling response between IL- 10 and RA bears
further investigation. Given that this swelling response is associated with damage to
network collagens, it is worthwhile to take advantage of biochemical techniques to assay
collagen damage. Antibodies to type IX collagen [134] and type II collagen [60] have been
use to evaluate stromelysin or APMA treated explants and would be of great use here to
determine if the difference in swelling response between IL- 10 and RA treatment correlates
with biochemical assays for collagen damage.
The results of Chapter III and appendix F motivate exploration of use of IL-10 in
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an in vivo environment. The upregulation of MMP production induced by IL-1 # and the
use of a synthetic inhibitor to prevent stromelysin degradation in vivo as well as inhibition
of IL-10 degradation in vitro combine to suggest experiments which assess the ability of
MMP inhibitors to prevent IL-1# induced degradation in vivo. These experiments not only
involve degradation which may involve other proteinases besides MMPs, but contain the
added complication over stromelysin experiments in that they require inhibitors to penetrate
the cartilage matrix to prevent degradation.
6.2.3 Mechanical Stimuli
Production and expression of MMPs are upregulated in animal models of experimentally
induced arthritis [96,100]. These models typically involve surgical alteration of joints and
result in abnormal joint loading. This appears to suggest a scheme of MMP regulation
that is influenced by mechanical loading. It is possible to evaluate this hypothesis more
rigorously by imposing deformations or loads in a more well-defined geometry. Several
studies have demonstrated alterations in biosynthetic rates of cartilage explants due to the
influence of mechanical stimuli [67,68,104-106]. In particular, it has been demonstrated
that large amplitude compressive strains induce degradation of tissue proteoglycans and
collagens [103]. The mechanism by which this degradation occurs is still unknown. Given
the ability of MMPs to degrade cartilage matrix (Chapters II, III, and IV) and the degradative
capacity of MMPs present in the tissue (Chapters IV and V), the hypothesis that MMPs
could be involved in this degradation seems reasonable. The use of MMP antibodies [74],
immunolocalization techniques [13,95], and analysis of degradation fragments [108] would
prove very useful in assessing the role of MMPs in mechanically mediated tissue catabolism.
As with other experiments, the translation to an in vivo system seems to be a logical
extension of these experiments. An animal model n place at Merck Research Laboratories
involves cartilage degradation induced by a partial transection of the medial meniscus of
guineau pigs. This model is known to result in degradation similar to arthritis. Measuring
the electromechanical behavior of cartilage from these animals using a plane-ended indenter
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(Appendix E) would give more insight into the degradative process resulting from abnormal
joint loading. Additionally the use of MMP inhibitors to prevent this degradation could
give valuable insight into mechanisms of joint deterioration in this model.
6.2.4 Tissue Regrowth
Several investigators have studied the metabolic and biochemical responses cartilage ex-
plants to degradation induced by enzymes such as chymopapain [125,132,133] or chon-
droitinase ABC [107]. In these studies, the cartilage explants responded to the proteoglycan
depletion induced by enzymatic treatment by upregulating proteoglycan synthesis. Using
stromelysin to degrade the matrix and evaluating the metabolic response would be inter-
esting in that chondrocytes may respond differently to an enzyme which is native to the
tissue. The mechanism by which the cartilage cells respond to this degradation are relevant
to an in vivo disease state where a damaged matrix can regrow if further degradation can
be prevented. In theory, this regrowth could be altered by the introduction of mechanical
stimuli which have been shown to upregulate cartilage biosynthetic rates [103,105].
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Appendix A
Control Studies
A.1 Culture Protocol
In developing an experimental system for the characterization of enzymatic degradation
of cartilage, it is of extreme importance to develop a reliable and reproducible protocol
for the culture of cartilage disks. The main requirement for such a system is that there
should be negligible matrix degradation in control samples over the time course of the
experiment. For studies involving treatment with exogenous enzymes or those designed to
assess degradation of cartilage matrix by endogenous proteinases, it is desirable to have a
closed system in terms of enzyme production. The implication is that amount of enzymes
to which a sample is exposed should be either the amount which was added to the system
(in the case of exogenous enzyme addition), or the amount which exists within the tissue
initially (for activation of endogenous proteinases). This allows for the assessment of the
effect of the particular treatment on the integrity of the matrix, without any mediation from
the cells.
Since chondrocytes are responsible for the maintenence of the cartilage matrix, they
contain several types of proteinases which are capable of altering matrix composition [90].
Indeed, this is quite necessary for the matrix turnover and remodeling which the chondro-
cytes modulate [18,50,54]. However, if the tissue were non-viable and the chondrocyte cell
membranes were ruptured, the proteinases stored within the cells would be released and be
free to degrade the matrix. This is clearly unacceptable if the system is to be well defined
and reproducible.
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A.2 Methods
Several culture protocols and systems were evaluated for suitability for use as controls for
enzymatic degradation studies. The use of frozen cartilage has the potential advantage of
experimental convenience, but the freezing process is likely to result in cell death and rupture
of cell membranes. To assess the effects of the freezing process on matrix degradation,
cartilage disks were harvested as described previously (Chapter 3) and frozen at -20 C
for 24 hours. Disks were thawed, then incubated in groups of 4 in 24-well culture dishes
in 1 ml phosphate buffered saline (PBS) at 370C in a 5% CO2 atmosphere and removed
from culture at times up to 48 hours. Groups of disks were incubated in PBS alone or
in the presence of 100 ig/ml bovine pancreas trypsin, 1000 /Ig/ml trypsin or a cocktail of
proteinase inhibitors. This inhibitor cocktail included 10 mM benzamidine hydrochloride
to inhibit trypsin-like activity, 10 mM N-ethylmaleimide to inhibit sulfylhydry-dependent
proteinases, 1 mM phenylmethanesulfonyl fluoride to inhibit serine proteinases such as
cathepsin B, 1 [M pepstatin to inhibit acid proteinases including cathepsin D.
Additionally, groups of plugs were harvested and immediately incubated in groups
of 4 in 1 ml Dulbecco's Modified Eagle Media (DMEM) containing 100 U/ml penicillin G
and 100 /g/ml streptomycin for approximately 16 hours at 37 oC in a 5% CO 2 atmosphere.
Groups of disks were then incubated in PBS, DMEM, DMEM with 10mM Na2EDTA
to inhibit metalloproteinase activity, or DMEM with 50 /g/ml trypsin and removed from
culture at times up to 72 hours.
After removal from culture, cartilage disks were frozen at -20'C, lyophilized, and
digested with 1 ml of 125 /g/ml papain digestion solution as described previously [105].
20 ILI portions of digests and culture media were assayed for sulfated GAG by reaction with
2 ml of dimethylmethylene blue dye solution in polystyrene cuvets and spectrophotometry
[34] using whale/shark chondroitin sulfate as the standard.
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Figure A. 1: Normalized GAG loss from previously frozen cartilage disks incubated in PBS
alone or in the presence of 100 mug/ml trypsin, 1000 mug/ml trypsin or a cocktail of pro-
teinase inhibitors including 10 mM benzamidine hydrochloride, 10 mM N-ethylmaleimide,
1 mM phenylmethanesulfonyl fluoride, 1 /LM pepstatin. Data are mean ± SD (n=4).
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Figure A.2: Normalized GAG loss from fresh cartilage disks incubated in PBS, DMEM,
DMEM with 10 mM Na2EDTA, or DMEM with 50 ug/ml trypsin. Data are mean ± SD
(n=4).
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A.3 Results
Culture of frozen tissue in the absence of proteinase inhibitors resulted in >80% GAG loss
after only 1 day in culture, while addition of the inhibitor cocktail prevented degradation to
the extent that 5-,5% of GAGs were lost after 2 days in culture (Fig A. 1). Addition of either
100 1/g/ml or 1000 /ig/ml trypsin to the culture media resulted in rapid matrix degradation,
with >90% GAG loss after only 3 hours in culture. Cartilage disks from all conditions
which were cultured immediately after explant showed little GAG loss in culture, with
the exception of those samples incubated in the presence of 50 ig/ml trypsin (Fig A.2).
Samples incubated in PBS, DMEM, or DMEM with Na2EDTA lost <5% of tissue GAG
after two days in cultured, while the addition of trypsin to the media yielded >90% GAG
loss after 6 hours.
A.4 Summary and Conclusions
Given that, in the absence of proteinase inhibitors, previously frozen tissue lost significant
amounts of GAG in less than 1 day, the use of such tissue for enzymatic degradation studies
is undesirable. While addition of an inhibitor cocktail eliminates this loss, their use is not
optimal since MMPs such as stromelysin are known to serve as activators for other enzymes
[119,120], and use of broad spectrum of inhibitors would mask these "cascade" effects.
Cartilage disks which were cultured immediately after harvest in either PBS or DMEM
showed negligible degradation without proteinase inhibitors after 48 hours in culture. With
longer media times, however, the use of DMEM would seem to be preferable to PBS, since
tissue cultured in only saline would likely start to suffer from nutritional deprivation.
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Appendix B
Assessment of Cartilage Degradation
B.1 Physicochemical Measurements
The changes in cartilage composition which result from treatment with metalloproteinases
are accompanied by alterations in tissue physicochemical properties. As described by
Maroudas [77-79], the swelling state of cartilage is determined by a balance between the
osmotic pressure of the proteoglycans, which tends to swell the tissue, and the restraining
tensile forces of the collagen network, which tend to limit tissue swelling. Removal of
fixed charge groups on the proteoglycans would result in a decrease in osmotic swelling
pressure as well as in the solid mass of the tissue. Effects on the bulk wet weight are more
difficult to predict, given that the solid components lost by the tissue may be replaced by
water moving into the tissue, resulting in little change in net mass. Degradation of cartilage
collagens results in a damaged collagen network which is less able to counteract osmotic
swelling pressure. Maroudas [78] demonstrated that osteoarthritic cartilage swells by a
greater amount than normal cartilage when equilibrated in hypotonic saline, due to collagen
network damage. Given the multitude of physicochemical measurements which can be
recorded, it is important to evaluate which measurements are sensitive to the various matrix
degradation induced by different proteinases.
B.2 Methods
The femoropatellar groove of 1-2 week old calves was isolated and 3 mm diameter by
1 mm thick cartilage disks were harvested as described previously (Chap 2). Immediately
after explant, disks were incubated in groups of 4 in 1 ml DMEM containing 100 U/ml
penicillin G and 100/ g/ml streptomycin for approximately 16 hours at 37 C in a 5%
CO2 atmosphere. Groups of disks were incubated in DMEM alone or DMEM with 50 or
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500 /zg/ml recombinant human stromelysin (SLN), 100 pg/ml bovine pancreas trypsin, or
100 pg/ml recombinant human interstitial collagenase and removed from culture at times
up to 72 hours. Cartilage disks were matched such that at each time point, tissue samples
from all conditions originated from similar locations along the femoropatellar groove.
Upon removal from culture, groups of plugs were patted briefly with a paper towel to
remove surface water, and wet weights were measured. Disks were then twice reequilibrated
in 1 ml of hypotonic saline solution for 1 hour at room temperature. Surface water was again
removed and wet weights were measured. Following wet weight measurements, disks were
lyophilized, and dry weights were recorded. Values for tissue hydration were obtained by
normalizing tissue water weight (wet weight - dry weight) to tissue dry weight. Samples
were then frozen at -200 C, lyophilized and digested with papain.
B.3 Results
Cartilage samples incubated in the presence of 500 /g/ml SLN or 100 /tg/ml trypsin showed
significant loss of both tissue wet weight (Fig B.1) and dry weight (Fig B.2) as well as
significant increase in tissue hydration (Fig B.3). After three days in culture, samples treated
with 500 /zg/ml SLN had average dry and wet weight values which were -50% and -75%
of control values respectively, while those treated with 100 /g/ml trypsin were ,,50% and
~,70% of control values. Samples treated 50 ftg/ml SLN did not have significantly different
dry weight, wet weight, or hydration from controls after three days in culture.
Cartilage disks treated with 100 Itg/ml recombinant human interstitial collagenase
exhibited rapid GAG loss, with tissue GAG content decreasing to <5% of its initial value
after only 48 hours in culture (Fig B.4). Additionally, collagenase treated samples had an
increased swelling response, demonstrating significantly different swelling behavior from
control samples after only 12 hours in culture (Fig B.5). After 3 days in culture, tissue treated
with collagenase exhibited a swelling ratio of 1.1 ± 0.03, as compared to 1.02 ± 0.025 for
controls.
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Figure B. 1: Wet weights of cartilage disks incubated in DMEM alone or DMEM with
50 /g/ml recombinant human stromelysin (SLN), 500 /g/ml SLN, or 100 pg/ml bovine
pancreas trypsin. Data are mean - SD (n=4).
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Figure B.2: Dry weights of cartilage disks incubated in DMEM alone or DMEM with
50/ g/ml recombinant human stromelysin (SLN), 500 ig/ml SLN, or 100I g/ml bovine
pancreas trypsin. Data are mean + SD (n=4).
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Figure B.3: Hydration values for cartilage disks incubated in DMEM alone or DMEM with
50 pg/ml recombinant human stromelysin (SLN), 500 pg/ml SLN, or 100 /g/ml bovine
pancreas trypsin. Data are mean ± SD (n=4).
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B.4 Summary and Conclusions
Measurements of both cartilage wet weights are dry weights from samples treated with
either stromelysin or trypsin are consistent with the significant of the cartilage matrix.
As these enzymes react with their respective substrates in the tissue, proteoglycans and
other matrix constituents are lost from the samples, thus decreasing the measured mass.
Both of these measurements, however, depend on the specimen size, which may vary from
sample to sample. This is of particular concern, given that samples were experimentally
matched across conditions at any given time point, but not necessarily matched across all
times. This is particularly evident in dry weight measurements, were the mass of control
samples in culture for 72 hours was different from those removed from culture at the start
of the experiment (Fig B.3). The lack of consistent data for controls during the time of the
experiment, makes interpretation of treatment groups more difficult. In theory, hydration
measurements have the advantage of normalizing samples water content to tissue dry weight.
However, in systems for which the the dry mass is not constant, this normalization becomes
less advantageous. Consequently, the physical relevance of extremely large hydration
values observed for tissue treated with large doses of either stromelysin or trypsin (Fig B.3)
in unclear. An increase in hydration typically implies that the sample has taken up water,
whereas in these cases it likely involves no water uptake, but rather loss of solid mass.
In separate experiments, control and collagenase-treated samples were weighed
upon removal from culture, then reequilibrated in hypotonic saline and weighed again.
The weight in hypotonic saline was then normalized to wight in culture media to give a
swelling ratio (Fig B.5) which is independent of sample size. Indeed, control samples
incubated in DMEM alone showed relatively constant swelling ratio over 3 days in culture
(Figure B.4). An increase in swelling ratio implies damage to the tissue network collagens,
which are unable to resist the swelling pressure of the proteoglycans. Treatment with
100 ,/g/ml recombinant human interstitial collagenase did result in an increase in swelling
ratio, consistent with the known activity of this enzyme against type II collagen.
The large loss of GAG induced by treatment with interstitial collagenase is inherently
Section B.4
-131-
1
u 0.8
U,
F- 0.6
LU
N
•j 0 .4
0 0.2
Z
0
0 24 48 72
TIME, hr
Figure B.4: Normalized GAG loss from cartilage disks incubated in DMEM alone or
DMEM with 100 pg/ml recombinant human interstitial collagenase. Data are mean + SD
(n=4), reported as GAG remaining in the tissue normalized to total GAG (tissue + media
GAG) at each time point.
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Figure B.5: Swelling ratio (wet weight in 0.01 M NaCI normalized to wet weight in DMEM)
of cartilage disks cultured in DMEM alone or DMEM with 100 /zg/ml recombinant human
interstitial collagenase. Data are mean + SD (n=4).
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interesting. Collagense is capable cleaving the aggrecan core protein in the interglobular
domain, just as stromelysin. However, its primary degradative activity is thought to be
against type II collagen. This aggressive degradation of proteoglycan then brings into
question the stability of the enzyme. Upon further analysis, it was determined that the
active collagenase had indeed auto-lysed, resulting in several smaller forms of the enzyme
(M. W. Lark, personal communication). These smaller forms likely lose their specificity
for type II collagen and exhibit normal MMP activity against proteoglycan, resulting in the
significant loss of GAG seen here (Fig B.4).
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Appendix C
Stromelysin Reaction Kinetics
C.1 Transport and Reaction
In characterizing the kinetics of loss of proteoglycan fragments from explants exposed
to recombinant human stromelysin, there are a number of transport and reaction events
which may be rate limiting. Given the sizes of the active enzyme (-46 kDa) and cleaved
aggrecan fragments (>200 kDa), it is likely that their respective transport into and out of
the intact cartilage matrix is hindered considerably. Consequently, upon initial exposure,
stromelysin is unable to penetrate the dense matrix and is only able to degrade the matrix
near the tissue surface. With time, degradation progresses from the tissue surface, and the
enzyme is able to diffuse more easily through the degraded matrix and access substrate in
deeper portions of the tissue. In this scheme, a front of degradation moves into the tissue
from the surface, and the rate of loss of proteoglycan fragments to the culture media is
determined by the kinetics of the reaction between the enzyme (stromelysin) and substrate
(aggrecan) producing a product (proteoglycan fragment). The kinetics of such a reaction
were described by Michaelis and Menten [118].
C.2 Michaelis-Menten Kinetics
In this treatment, the following components are considered: the enzyme (E), the substrate
(S), the enzyme-substrate complex (ES) and the product (P).
E+S , ES E +P (C.1)
k2
At steady state, there is no net accumulation or disappearance of enzyme-substrate complex,
and thus:
kl[E][S] = (k2 + k3)[ES] (C.2)
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Rearranging to obtain an expression for equilibrium:
[E][S] k2 + k3[ES] = where kM = (C.3)
kM kl
Assuming reaction rates are relatively fast, then the number of enzyme-substrate complexes
is relatively small compared to amounts of enzyme, substrate, or product, and thus at all
times:
[Sol] = [S] + [P] (C.4)
The rate of generation of product is then equal to the rate of disappearance of reactant.
d[P] d[S] [E][S]
- - k3 (C.5)dt dt km
Separating variables gives Its] d[S] t k3[E]
[ - dt (C.6)- Jsol [S] km
and integration yields
[S] k3[E]
- In [ t (C.7)
[So] kM
thus
= et/ where 1 k3[E] (C.8)
[So] 7 km
The major consequence of such a development is that for a system which is dominated
purely by the kinetics of an enzyme-substrate reaction, the rate of consumption of substrate,
in this case cartilage matrix proteoglycan, will be exponential with time. Furthermore, the
time constant, 7, for the degradation of matrix proteoglycan, is inversely proportional to the
amount of enzyme to which the tissue is exposed.
The data in figure 2.1 show the loss of tissue proteoglycan with time in culture
from samples treated with graded levels of active stromelysin. The data for each enzyme
concentration are fit to a single exponential of the form e- t/'. In figure A. 1, the inverse
time constant (1/7-) was plotted against stromelysin dose. All data points are N = 2, with the
Section C.2
-136-
5x10-5
4x10-s
3x10 -5
-2x10-
0
0 100 200 300 400 500
[SLN] (gg/ml)
Figure C.1: Inverse time constant of proteoglycan loss plotted against concentration of
stromelysin in culture media. Values of r were obtained at each concentration by fitting the
times course of proteoglycan loss to an exponential of the form e- t/ ' (See Fig 2.1).
exception of 100 (N = 5) and 10 pg/ml SLN (N = 3). The data were fit by linear regression
and yielded a best fit slope of 4.37 m ,o corresponding to the ratio k3/kM. Given that the
data for matrix degradation match well with reaction kinetics, it seems likely that there is
little or no penetration of the active enzyme into the undegraded matrix.
This is also consistent with histology performed on stromelysin-treated cartilage
(Fig 2.3) which demonstrates a marked boundary between the degraded surface region and
undegraded inner portion of the tissue. This correlation between histological evidence
and GAG data is also quantitative, given that histology showed that proteoglycans were
removed from a region which penetrated - 150 jm into the sample on all sides of the 3 mm
diameter, 1 mm thick disk, leaving a disk with a degraded surface region and an inner core
2.7 mm in diameter and 0.7 mm thick which is undegraded. A comparison of undegraded
Section C.2
-137-
volume (4.01 mm3) to total volume (7.07 mm 3), shows a fractional GAG content of 56.7%,
as compared to the measurement of 50.1% by the DMB dye binding assay.
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Appendix D
Inhibitor Studies
D.1 Introduction
Inhibitors of MMPs which are native to cartilage, such as TIMP and a 2-M, are generally
quite large. Consequently, the transport of such large proteins through the dense cartilage
matrix is typically hindered significantly [79]. As a result, there has been a significant
effort to design low molecular weight inhibitors which would have more favorable transport
characteristics. Several classes of inhibitors have been developed, including those which
bind to the enzyme active site [1] and other which attach to propetide regions [38]. In
general, the efficacy of such inhibitors has been evaluated by characterizing their ability to
inhibit the reaction of a given enzyme to an isolated substrate in solution. While this allows
for very precise quantitation of reaction kinetics, it does not account for transport through
the cartilage matrix, which can have a profound effect on inhibitor efficacy.
The addition of APMA to cartilage explants has been shown to result in significant
degradation of matrix proteoglycans and collagens, due to activation of endogenous MMPs
[9]. Since APMA is relatively small (,- 350 Da) its transport through cartilage is relatively
unhindered and the resulting degradation should be distributed throughout the matrix. Such
a culture system is well suited for evaluation of inhibitor efficacy, in that any such inhibitor
would be required to penetrate the cartilage matrix to effectively inhibit the MMPs activated
by APMA. Similarly, treatment with either IL- 10 or RA results in the production of MMPs
by chondrocytes, and inhibition of these enzymes would require diffusion of inhibitors from
the culture media into the cartilage matrix.
Several N-carboxyalkyl peptide inhibitors [22] were evaluated for their ability to
inhibit cartilage matrix degradation resulting from APMA activation of MMPs. These
peptide inhibitors contain chelating groups and are designed to bind to the active site of
an MMP and remove the Zn+ bound to the enzyme. The removal of the metal ion results
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Inhibitor ki vs. ki vs. Molecular
Stromelysin Collagenase Weight
MCI 310nM 750 nM 476
MC2 230nM 470 nM 483
MC482 30 nM 5.7 MM 594
MC561 4.2 IM 660 nM 467
MC354 30nM 300 nM 498
TIMP <0.1 nM <0.1 nM 28000
Table D.1: Coefficients of inhibition against stromelysin and collagenase and molecular
weights of metalloproteinase inhibitors MC1, MC2, MC482, MC561, MC354, and TIMP.
Values of k, of synthetic inhibitors were measured for inhibition of reaction of MMPs
against a peptide-modified substance P.
in a conformational change which renders the enzyme inactive [22]. (These inhibitors
were graciously provided by Dr. William K. Hagmann, Merck Research Laboratories.)
Four synthetic compounds were tested: L-696,418 (MC1), L-702,842 (MC2), L-744,482
(MC482), L-707,346 (MC562), L-712,354 (MC354) and compared to TIMP for their ability
to inhibit matrix degradation induced by stromelysin, APMA, IL- 10 or RA. MC 1, MC2 and
MC354 are broad spectrum MMP inhibitors. MC482 is primarily a stromelysin inhibitor,
with low efficacy against collagenase. MC5621 is primarily a collagenase inhibitor, with
low efficacy for stromelysin. Relative efficacy of compounds is determined by comparison
of reaction constant (kl) characterizing the inhibition of enzymatic cleavage of a peptide-
modified substance P [22]. A lower value of ki indicates that a smaller amount of an
inhibitor is required to yield a given amount of inhibition. Therefore, inhibitors with the
lowest values of ki are the most potent inhibitors. Values of ki for these inhibitor against
MMPs are shown in table D. 1.
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D.2 Methods
The femoropatellar groove of 1-2 week old calves was isolated and 3 mm diameter by
1 mm thick cartilage disks were harvested as described previously (Chap 2). Immediately
after explant, disks were incubated in groups of 4 in 1 ml DMEM containing 100 U/ml
penicillin G and 100 tg/ml streptomycin for approximately 16 hours at 37 0 C in a 5%
CO 2 atmosphere. Groups of disks were incubated in DMEM with 100 pg/ml recombinant
human stromelysin (SLN). After 12 hours in culture, 2 /g/ml MC1 was added to the culture
media of half the groups. In separate experiments, groups of cartilage disks were incubated
in DMEM alone, DMEM with 1 mM APMA, or DMEM with 1 mM APMA plus graded
levels of MMP inhibitors MC1, MC2, MC482, MC561, or TIMP ranging from 40 nM to
4 pM. Cartilage disks were removed from culture at times up to 72 hours for biochemical
analysis and swelling studies. In a third set of experiments, groups of plugs were treated
with 100 ng/ml IL-1 f# or 1 ILM RA in the presence and absence of synthetic inhibitors MC 1
and MC354. Cartilage samples were incubated for up to 8 days, with media changes every
2 days.
For swelling studies, after removal from culture, groups of plugs were patted briefly
with a paper towel to remove surface water, and wet weights were measured. Disks were
then twice reequilibrated in 1 ml of hypotonic saline solution for 1 hour at room temperature.
Surface water was again removed and wet weights were measured. Following wet weight
measurements, disks were lyophilized, and dry weights were recorded. Values for tissue
hydration were obtained by normalizing tissue water weight (wet weight - dry weight) to
tissue dry weight. Samples were then frozen at -20 C, lyophilized and digested with papain.
D.3 Results
Addition of 2 /g/ml MC1 to culture media containing 100 /tg/ml SLN after 12 hours of
incubation prevented further loss of GAG from cartilage explants (Fig D. 1). After 12 hours
in culture, SLN treatment induced (- 15%) loss of GAG from cartilage disks, and this loss
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continued to the point where >70% of GAG was lost from samples which received no
inhibitor. Plugs which received MC1 12 hours into culture showed no significant GAG loss
after treatment.
Cartilage plugs incubated in the presence of 1 mM APMA in the absence of MMP
inhibitor lost >60% of tissue GAG after 3 days in culture. Samples cultured with 2 pg/ml
MC 1, 2 pg/ml MC2, or 100 jig/ml TIMP in addition to 1 mM APMA did not show significant
GAG loss after three days in culture (Fig D.2). Incubation of cartilage disks in 1 mM APMA
plus 2 pg/ml MC482 or 2 pg/ml MC561 resulted in 20% and 50% loss of GAG, respectively,
compared to 80% loss of GAG for samples treated with 1 mM APMA and no inhibitor (Fig
D.3). Samples treated with APMA without inhibitor had a swelling ratio of 1.13 after three
days in culture, compared to 1.10 and 1.05 for samples treated with APMA and MC561 or
MC482 and 1.03 for controls in DMEM alone (Fig D.4).
Dose response experiments showed that 2, 0.2 and 0.02 /Ig/ml MC482 inhibited
APMA-induced GAG loss by 85%, 55%, and 10% respectively (Fig D.5). Similar exper-
iments showed that 2, 0.2 and 0.02 jg/ml MC561 inhibited APMA-induced GAG loss by
40%, <5%, and <5% respectively (Fig D.6). These data, combined with similar data for
MC1 and TIMP (see chapter 4) are plotted as percentage inhibition of GAG loss at 72
hours in culture vs dose of inhibitor (Fig D.7). These data show that for all doses used,
MC1 was the most effective inhibitor of APMA induced degradation. TIMP and MC482
showed similar efficacy across the range of doses used, while MC561 was the least effective
inhibitor, showing only moderate efficacy at the highest dose used.
Cartilage disks cultured in the presence of 0.1% BSA with 2 tg/ml MC1 and 1 mM
APMA lost -30% of tissue GAG after three days in culture, compared to <5% for controls
or disks cultured in 2 jg/ml MC1 and 1 mM APMA and 60% loss from samples cultured
in 1 mM APMA (Fig D.8).
Cartilage disks cultured in the presence of 100ng/ml IL-10 lost >90% of tissue
GAG content after 8 days in culture, while samples treated with 100ng/ml IL-10 plus
100 jiM MC354 exhibited <40% loss of GAG, compared to ,20% for controls (Fig D.9).
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Figure D. 1: Normalized GAG loss from cartilage disks incubated in DMEM with 100 /zg/ml
recombinant human stromelysin in the presence and absence of 2 Ag/ml MC1, added 12
hours after the start of culture. Data are mean + SD (n=4), reported as GAG remaining in
the tissue normalized to total GAG (tissue + media GAG) at each time point.
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Figure D.2: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 mM APMA, DMEM with 1 mM APMA plus 2 jig/ml MC1, or DMEM with 1 mM
APMA plus 2 /g/ml MC2. Data are mean + SD (n=4), reported as GAG remaining in the
tissue normalized to total GAG (tissue + media GAG) at each time point.
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Figure D.3: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 mM APMA, DMEM with 1 mM APMA plus 2 ig/ml MC561, or DMEM with 1 mM
APMA plus 2 [g/ml MC482. Data are mean + SD (n=4), reported as GAG remaining in
the tissue normalized to total GAG (tissue + media GAG) at each time point.
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Tissue samples cultured in the presence of 1 p M RA lost >60% of tissue GAG content
after 8 days in culture, while samples treated with 1 pM RA plus 100 pM MC354 exhibited
<30% loss of GAG, compared to ~20% for controls (Fig D.10). Cartilage disks treated
with 100 ng/ml IL-10 demonstrated an increase in swelling ratio after 8 days in culture,
which was inhibited by the presence of 100 /tM MC1. Tissue samples treated with 1 pM
RA with or without 100 /tM MC1 did not exhibit changes in swelling behavior over 8 days
in culture (Fig D. 11).
D.4 Summary and Discussion
The inhibition of SLN- and APMA-induced GAG loss by MC1 (Figs D. 1 and D.2) demon-
strated that the N-carboxyalkyl peptides are cablable of inhibiting MMPs in an organ culture
environment. It is likely, however, that inhibition took place in the culture media for SLN
degradation (Fig D.1), given that previous studies have shown this degradation proceeds
inward from the tissue surface [8]. This is not the case, however, for APMA-induced
degradation, which likely occurs throughout the tissue. It is noteworthy then that MC1,
MC2, and TIMP all were able to completely inhibit GAG loss in this system. The levels of
TIMP and MC1 are identical to those used in previous experiments [9] which also resulted
in complete inhibition. Given that values of k, for MCI and MC2 are similar, it is not
surprising MC2 was able to inhibit GAG loss is this system as well.
Given that APMA activates a wide range of MMPs, the use of inhibitors specific to
only one enzyme can give information about the relative impact of an enzyme on a given
process. Used in similar doses, MC482 was more effective at inhibiting APMA-induced
GAG loss than MC561 (Fig D.3). Given that MC482 is more potent against stromelysin,
MC561 is more potent against collagenase, this suggests that in this system, inhibition
of stromelysin is more critical for maintaining tissue proteoglycans. Curiously, MC482
was also more effective at inhibiting tissue swelling than MC561, seemingly implying that
inhibition of stromelysin is critical to the maintenence of the collagen network also. Given
that stromelysin is known to degrade type IX collagen but only slightly degrade type II
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Figure D.4: Swelling ratio (wet weight in 0.01 M NaCl normalized to wet weight in DMEM)
cartilage disks incubated in DMEM alone, DMEM with 1 mM APMA, DMEM with 1 mM
APMA plus 2 /g/ml MC561, or DMEM with 1 mM APMA plus 2 /Ig/ml MC482. Data
are mean + SD (n=4), reported as GAG remaining in the tissue normalized to total GAG
(tissue + media GAG) at each time point.
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Figure D.5: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 mM APMA, or DMEM with 1 mM APMA plus graded levels of MC482 ranging
from 0.02 /tg/ml to 2 /zg/ml. Data are mean ± SD (n=4), reported as GAG remaining in the
tissue normalized to total GAG (tissue + media GAG) at each time point.
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collagen, while collagenase in known to cleave type II but not type IX collagen this may
indicate that type IX collagen plays an important role in maintaining collagen network
integrity. While this is potentially a very interesting hypothesis, the spread of the swelling
data make it difficult to make definite conclusions.
The dose response curves for MC482 (Fig D.5) and MC561 (Fig D.6) are consistent
with previous data for these inhibitors gathered at high concentration. Doses of 2 and
0.02 j/g/ml MC482 yield 85% and 50% inhibition of GAG loss respectively, while the
2 pg/ml MC561 yields <50% inhibition. MC482 is more than an order of magnitude more
effective at inhibiting GAG loss in this system, presumably due to the more significant role
of stromelysin in degrading matrix proteoglycans.
Given this data, it is logical to use ki against stromelysin as criteria for predicting
the ability of an inhibitor to prevent GAG loss. Comparing several of the inhibitors tested
here (Fig D.7) demonstrates that this thought model is not sufficient to explain the observed
phenomena. While MC482 was more effective at all concentration than MC561, it was not
as effective as MC1, an inhibitor which was shown to be less effective against stromelysin
than MC482 in solution studies [22]. In addition, TIMP, which is known to be several orders
of magnitude more potent against MMPs in solution than any of the synthetic inhibitors used
here was in fact less effective at preventing GAG loss than MC1. While the difference in
transport characteristics between TIMP and the small peptides may account for differences
in efficacy in intact tissue, it serves to emphasize the fact that there may not be a one to one
correspondence between efficacy of a given inhibitor in solution and in tissue.
While inhibitor size is a factor which clearly contributes to transport characteristics,
other factors, such as non-specific binding of inhibitors to endogenous proteins can dramat-
ically alter inhibitor transport and ultimately inhibitor efficacy. In experiments assessing
inhibition of APMA-induced GAG loss by MC1, the addition of 0.1% BSA to the culture
media significantly decreased the level of inhibition. The level of inhibition of 2 /Ig/ml
MC 1 in the presence of 0.1% BSA was similar to that of 0.02 [g/ml MC 1 with no BSA (see
chapter 4). Given that MC1 does exhibit non-specific protein binding (Dr. Michael Lark,
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Figure D.6: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 mM APMA, or DMEM with 1 mM APMA plus graded levels of MC561 ranging
from 0.02 pg/ml to 2 /g/ml. Data are mean ± SD (n=4), reported as GAG remaining in the
tissue normalized to total GAG (tissue + media GAG) at each time point.
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Figure D.7: Percentage inhibition of GAG loss due to APMA treatment plotted against
inhibitor concentration, for inhibitors MC1, MC482, MC561, and TIMP.
Section D.4
MC1
L.
Cu
0
-I
0
'I-0z
ORI-
-z
-151-
0
LU
D
N
.1
cn
Z
1-
0.8-
0.6-
0.4-
0.2-
0
24
TIME, hr
48 72
Figure D.8: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 mM APMA, DMEM with 1 mM APMA plus 2 pg/ml MC 1, or DMEM with 1 mM
APMA plus 2 pg/ml and 0.1% BSA. Data are mean ± SD (n=4), reported as GAG remaining
in the tissue normalized to total GAG (tissue + media GAG) at each time point.
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personal communication), it seems likely that this binding decreases the amount of peptide
which is free to inhibit MMPs. This is potentially significant to inhibition of MMPs in vivo,
where synovial fluid contains high concentrations of protein such as albumin.
The inhibition of PG loss by MC354 consistent with previous studies using MMP
inhibitor to prevent degradation induced by treatment with IL-10 or RA [1,87,113]. While
the inhibition observed here is not complete (Fig D.8 and D.9), it is substantial and suggests
that MMPs play a role in the mechanisms of degradation in these systems. Given previous
studies, it is reasonable to hypothesize that complete inhibition of GAG loss could be
achieved by optimizing the level of MC354 used in the system. The difference in swelling
response between IL-10 and RA treatments is consistent with previous results in these
systems (Chapter V). The fact that the swelling response in these systems can be completely
inhibited suggests that collagen damage induced by IL-10 treatment can be prevented
more easily than damage to tissue PGs. This is similar to previous studies in which
an MMP inhibitor was able to inhibit loss of tissue hydroxyproline but not GAG [1].
Andrews at al have hypothesized that since collagen damage generally occurs later than PG
damage, it is possible that the PG matrix must be significantly degraded before collagen-
degrading enzymes have access to their substrates. Consequently, the proteases which
degrade collagen are more easily inhibited since they require longer times to take action.
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Figure D.9: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 100ng/ml IL-1,3, or DMEM with 100ng/ml IL-10 plus 100 pM MC354. Data are
mean ± SD (n=4), reported as GAG remaining in the tissue normalized to total GAG (tissue
+ media GAG) at each time point.
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Figure D. 10: Normalized GAG loss from cartilage disks incubated in DMEM alone, DMEM
with 1 jIM RA, or DMEM with 1 1iM RA plus 100 pM MC354. Data are mean ± SD (n=4),
reported as GAG remaining in the tissue normalized to total GAG (tissue + media GAG) at
each time point.
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Figure D.11: Swelling ratio (wet weight in 0.01 M NaCi normalized to wet weight in
DMEM) plotted against time in culture for samples incubated in DMEM alone, DMEM
with 100 ng/ml IL-13, DMEM with 100 ng/ml IL- 1 plus 100 LM MC 1, DMEM with 1 IM
RA, or DMEM with 1 tLM RA plus 100 IM MC1. Data are mean + SD (n=4).
Section D.4
5 Uggmi Mv4 A 1 gM RA + 50 gg/ml MC418
-156-
Appendix E
Indentation Studies
E.1 Introduction
Articular cartilage provides a load-bearing, low-friction surface that transmits and distrib-
utes stress in synovial joints. One of the earliest events in osteoarthritic degeneration of
cartilage is a molecular-level alteration of the tissue's extracellular matrix involving loss of
highly charged proteoglycan (PG) molecules and fibrillation and swelling of the collagen
network. The decrease in tissue fixed charge density that accompanies loss of matrix PGs
results in a decrease in tissue stiffness [79] and a marked decrease in cartilage's electroki-
netic transduction properties. Detection of early degenerative changes, when therapeutic
intervention might be most beneficial, is not presently available. We hypothesized that
detection of subtle changes in cartilage electrokinetic behavior might provide a sensitive
measure of early stages of OA-degeneration. It is advantageous to develop methods for non-
invasive surface electrokinetic spectroscopy that can image focal degradation of cartilage
during arthroscopy.
E.2 Methods
A 1 mm diameter plane-ended indentor was fabricated from plexiglas and implanted with a
50 pm silver/silver chloride electrode at the center of the indentation surface. The indentor
was mounted in the Dynastat mechanical spectrometer and used to characterize cartilage
on intact guinea pig stifle joints and 9 mm diameter by 1 mm thick cartilage disks explanted
from the femoropatellar groove of young calves.
Guinea pig joints or bovine cartilage disks were placed in insulating chambers
and bathed in phosphate buffered saline (PBS) at room temperature. The indentor was
positioned at the center of the bovine cartilage disks or at several points along the guinea
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pig femoropatellar groove. Sequential increments of static strain were imposed on the
tissue up to 15% total compressive strain and dynamic strains of <1% amplitude were
superimposed on the static strains at frequencies ranging from 0.001 to 1 Hz. The static
and dynamic load signals from the load cell and streaming potential measured between the
indentor electrode and a reference electrode in the PBS bath were simultaneously recorded.
Measured load and streaming potential were normalized to imposed strains to give dynamic
stiffness and normalized streaming potential data.
E.3 Results
The magnitude of the dynamic stiffness and streaming potential increased with frequency
for both guinea pig and bovine cartilage. Values of dynamic stiffness ranged from -4
MPa at 0.002 Hz to 11 MPa at 1 Hz for both guinea pig (Fig E. 1A) and bovine cartilage
(Fig E. 1C). Streaming potential ranged from 5 [pV/% at 0.008 Hz to 85 pV/% at 1 Hz
(Figs E.2A and E.2C). The phase angles of the dynamic stiffness had peaks at 0.03 Hz and
0.003 Hz for guineau pig (Fig E. 1B) and bovine cartilage (Fig E. 1D), respectively. Similarly
the phase angles of the streaming potential had peaks at 0.03 Hz and 0.003 Hz for guineau
pig (Fig E.2B) and bovine cartilage (Fig E.2D), respectively.
E.4 Summary and Discussion
Both types of cartilage exhibit a frequency response typical of poroelastic behavior. This
is characterized by high and low frequency plateaus in magnitude, where the stiffness is
relatively constant with respect to frequency and the phase angle is low; and a range of
frequency in which there is transition from low to high frequency behavior where, the phase
angle is high due to friction between and moving fluid and the stationary matrix.
The streaming potential of cartilage on the intact guinea pig joint and the bovine
disk ranged from approximately 5 [V/% at 0.002 Hz to 90 p/V/% at 1 Hz and exhibited
frequency behavior similar to the dynamic stiffness. It is interesting to note that the peak in
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Figure E.1: Schematic illustration of experimental protocol for characterizing electro-
mechanical behavior of cartilage on intact joints using a plane-ended indentor.
Section E.4
|I
-159-
Guinea Pig
Joint Cartilage
I II I I I
E
a-
(1
U)
4)am
I-
0)0
z
0.0010.01 0.1
FREQUENCY, Hz
0.01 0.1
FREQUENCY, Hz
Figure E.2: Frequency response of dynamic stiffness magnitude (A) and phase angle (B) of
guinea pig femoropatellar groove cartilage as measured on bone with plane-ended indentor.
Frequency response of dynamic stiffness magnitude (C) and phase angle (D) of explanted
bovine cartilage disk as measured with plane-ended indentor.
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Figure E.3: Frequency response of streaming potential magnitude (A) and phase angle
(B) of guinea pig femoropatellar groove cartilage as measured on bone with plane-ended
indentor. Frequency response of streaming potential magnitude (C) and phase angle (D) of
explanted bovine cartilage disk as measured with plane-ended indentor.
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the phase angle of both stiffness and streaming potential differed significantly between the
guinea pig and bovine cartilage samples. This is consistent with the difference in sample
dimensions as well as tissue modulus and permeability. The thickness of the guinea pig
cartilage was approximately 100 pm compared to the 1 mm cartilage disk. The increase in
path length required for the fluid to leave the bovine samples pushes the peak in phase to
lower loading frequencies, where the fluid has time to leave the tissue.
In addition frequency dependence of the fluid flow allows the streaming potential
to be used as a detector of the spatial distribution of charge groups and thus as an indicator
cartilage degradation. Previous studies using cartilage explants have shown that streaming
potential measurements are capable of detecting the initial, focal degradation induced by
enzymatic degradation. Studies are underway which are using this indentation device to
detect small scale focal degradation of intact joints induced by enzymes and experimental
models of osteoarthritis.
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Appendix F
IL-13 In Vivo Studies
F.1 Introduction
The results from Chapter V and previous studies of IL-i 1 -induced degradation of cartilage
explants motivates application of this model to an in vivo system. While IL- 10 is known to
upregulate chondrocyte expression and production of MMPs [63,64], degradation products
which result in these culture systems are not those typically associated with MMP cleavage
[108]. Given that APMA has been shown to be effective at activating endogenous MMPs,
its use in conjunction with IL- 10 should result in significant matrix degradation attributable
to MMPs. The toxic nature of APMA requires that IL- 10 be administered first, upregulating
the production of latent MMPs. The susbsequent treatment with APMA should then activate
these MMPs which are free to degrade the matrix.
F.2 Methods
6-8 week old NZW female rabbits received intraarticular injections of 100 pg of recombinant
human interleukin-/10 (IL-10) in buffer into one hind stifle joint, with the contralateral
control joint receiving only buffer. After 16 hours, animals received a second intraarticular
injection of 1 mM APMA in both knees to activate endogenous MMPs. One hour after
APMA treatment, the animals were sacrificed and joints were lavaged with 1 ml PBS. Upon
sacrifice, stifle joints were isolated and stored at -700 C for up to three months. After thawing,
stifle joints were dissected and 3 mm cartilage/bone cylinders were cut from femoropatellar
groove using a dermal punch.
Immediately prior to mechanical testing, the cartilage was separated from the bone,
with care take to ensure that articular surface was placed in the confined compression
chamber in anatomic orientation (with articular surface up and bone/cartilage interface
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down). Cartilage plugs were tested in uniaxially confined compression using a Dynastat
mechanical spectrometer to measure the dynamic stiffness and streaming potential in the
0.005 to 1 Hz range, and equilibrium modulus, hydraulic permeability, and electrokinetic
coupling coefficient, using established methods [41]. After mechanical testing, cartilage
samples were lyophilized and digested with papain. Testing media and papain-digested
plugs were analyzed for GAG by DMB dye binding as a measure of PG loss.
F.3 Results
Intraarticular injection of IL-10 followed by injection of APMA did not induce significant
loss of GAG from femoropatellar groove cartilage compared to tissue from contralateral
control joints which received injection of only APMA (Fig F.1). With values from 2-3
disks averaged for each joint, the streaming potential at 1 Hz and electrokinetic coupling
coefficient of disks decreased significantly (p<0.05 and p<0.05) for joints treated with
100 ng IL- 1/ prior to APMA treatment (Fig E 1). Changes in equilibrium modulus, dynamic
stiffness at 1 Hz and hydraulic permeability were not significant (p>0.05) in these animals
(Fig F.1).
E4 Summary and Discussion
The changes in properties of rabbit knee cartilage exposed to rhIL-10 in vivo without
intravenous inhibitor resemble changes in calf explants after limited exposure to rhSLN in
vivo [9]. After 16 hours of IL-10 exposure followed by activation of MMP by injection
of APMA, there was little GAG loss and no associated change in mechanical properties,
but significant decreases in high frequency streaming potential and electrokinetic coupling
coefficient, consistent with PG degradation limited to the tissue surface [39]. Due to the
size of IL-10/ (18 kD), its transport through the cartilage matrix is hindered significantly.
Consequently, only cells near the tissue surface were stimulated by IL-1/, resulting in
the production of latent MMPs in this region. The subsequent injection of APMA likely
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Figure F. 1: Normalized streaming potential at 1 Hz, electrokinetic coupling coefficient, dy-
namic stiffness at 1 Hz, equilibrium modulus, and hydraulic permeability of cartilage disks
from lapine stifle joints which received intraarticular injection of 100 Lg IL- 1f followed
by 1 mM APMA and from contralateral control joints which received only 1 mM APMA.
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resulted in activation of these proenzymes, causing matrix degradation. Previous studies in
which SLN treatment caused loss of GAG in regions of the matrix near the articular surface
resulted in significant changes in electromechanical behavior, but little change in purely
mechanical behavior [9], similar to the results seen here.
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Appendix G
IL-1 Media Fragment Analysis
G.1 Introduction
The ability of TIMP and MC354 to partially inhibit proteoglycan loss from IL-1/3 or RA
treated samples, combined with previous reports of inhibition using synthetic MMP in-
hibitors [16,87,113] necessitates the characterization of proteoglycan fragments in these
systems. While stromelysin cleaves at the VDIPEN-FFGVG site in the aggrecan inter-
globular domain, the predominant site of cleavage observed in these systems as well as
in synovial fluid from human OA patients is the NITEGE-ARGSVIL site [108,111]. The
activity responsible for the generation of this cleavage has been termed "aggrecanase"
activity.
G.2 Methods
Cartilage disks, 3 mm diameter x 1 mm thick, were harvested from the femoropatellar
groove of 1-2 week old calves using a dermal punch and sledge microtome. Groups of 4
plugs were maintained in culture at 37 'C in a 5% CO 2 atmosphere for up to 8 days in 1 ml
DMEM containing either 1 mM 100 ng/ml recombinant human IL- 10, or 1 /LM retinoic acid
(RA) in 0.1% dimethylsulfoxide in the presence or absence of 100 t1M MC354, with fresh
media changes every two days.
Portions of culture media were treated with chondroitinase ABC to deglycosylate
the aggrecan core protein. Degradation products of aggrecan in culture media were detected
by western blot analysis. Antibodies raised against aggrecan GI domain (anti-ATEGQV),
and the NITEGE and ARGSVI epitopes in the interglobular domain [36,72] were used to
detect the presence of proteoglycan fragments in culture media. Portions of culture media
from days 2, 4, 6, and 8 were fractionated on SDS-PAGE and electroblotted onto a PVDF
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membrane for western blot detection of aggrecan cleavage fragments.
G.3 Results
Western blot analysis using the anti-ATEGQV Gl antibody revealed the presence of the
two band "aggrecanase" cleavage in media from IL-10f treated samples, running at approx-
imately 70 kD (Fig G.1). The release of fragments was slow on days 2 and 4, and much
greater on days 6 and 8. The 50 kD band, indicative of stromelysin-generated aggrecan
fragments, which was present in bovine meniscus and rat chondrosarcoma Al, was not
present in media from IL-10f treated samples.
The use of the anti-NITEGE antibody again demonstrated the slow release of
NITEGE fragments on days 2 and 4, with more massive release on days 6 and 8 from
samples treated with IL-10 (Fig G.2). The addition of MC354 to the culture media inhib-
ited the release of these aggrecanase-generated cleavage fragments. The Western blot with
the anti-ARGSVIL (BC-3 [36]) antibody shows the release of several sized fragments with
the N-terminus ARGSVIL due to IL-10 treatment (Fig G.3). The 220kD product is the
intact core protein cleaved at the ARGSVIL site, while the broad bands at 150 and 70 kD
are likely species with the N-terminus ARGSVIL and different C-terminii. The release
of ARGSVIL fragments of all sizes was slowed by the addition of MC354 to the culture
media.
G.4 Summary and Discussion
The partial inhibition by MC354 of GAG loss from IL-10 treated samples suggests that
there is either a primary proteinase activity which is being partially inhibited by MC354 or
that multiple proteinase activities are taking place, only some of which are being inhibited
by MC354. The data from analysis with the anti-ATEGQV antibody shows that there is in
fact only one fragment being generated in this system (Fig G. 1) and that it is the fragment
associated with aggrecanase activity. This is consistent with previous studies of similar
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Figure G.1: Western blot analysis of media samples from IL-10 treated samples. Media
from days 2, 4, 6, and 8 were analyzed with an antibody to the ATEGQV epitope in the first
fold of the G1 domain. Media fractions are compared to extracts from bovine meniscus and
rat chondrosarcoma Al.
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Figure G.2: Western blot analysis of media samples from samples treated with IL-10 or
IL-10 + MC354. Media from days 2, 4, 6, and 8 were analyzed with an antibody to the
NITEGE epitope in the interglobular domain of aggrecan. Media fractions are compared
to extracts from bovine meniscus Al.
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Figure G.3: Western blot analysis of media samples from samples treated with IL-1,3 or
IL-1/3 + MC354. Media from days 2, 4, 6, and 8 were analyzed with an antibody to the
ARGSVIL epitope (BC3) in the interglobular domain of aggrecan. Media fractions are
compared to extracts from bovine meniscus Al.
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culture systems [111]. Additionally, the generation of the C-terminal NITEGE fragment
(Fig G.2) and the N-terminal ARGSVIL fragments (Fig G.3) are clearly inhibited by the
addition of MC354 to the culture media. This implies that the mechanism responsible for
this "aggrecanase" activity involves MMPs and is consistent with the suggestion of other
investigators [36] that the enzyme responsible for this cleavage is an MMP.
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